L'archivio delle pubblicazioni di Fondazione ICONA

2023

A Tavelli, G Marchetti, A Vergori, E Quiros Roldan, V Malagnino, F Vichi, M Lichtner, S Nozza, R Rossotti, L Sarmati, F Bai, A Di Biagio, A Antinori, A d'Arminio Monforte, for ICONA Foundation Study Group Effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in real-world setting in ART-naive patients: data from ICONA Cohort 15° Congresso Nazionale ICAR - Bari, 14-16 Giugno 2023
S Lo Caputo, A Cozzi-Lepri, R Gagliardini, E Schiaroli, G Orofino, A Vergori, F Maggiolo, N Gianotti, A Castagna, A Cingolani, A Antinori, A d'Arminio Monforte, for ICONA Foundation Study Group Effectiveness of first-line lamivudine-dolutegravir (3TC-DTG) antiretroviral therapy (ART) in persons living with HIV (PLWH): real-life data from ICONA Foundation Cohort 15° Congresso Nazionale ICAR - Bari, 14-16 Giugno 2023
F Bai, M Ponzano, F Bovis, A di Biagio, G Guaraldi, A Rodanò, C Stingone, R Marocco, D Leoni, A Cozzi-Lepri, A d’Arminio Monforte, G Marchetti Body weight and plasma lipids changes in person living with HIV (PLWH) starting double or triple INSTI-based cART regimens 15° Congresso Nazionale ICAR - Bari, 14-16 Giugno 2023
GV Calvino, M Errico, A Tavelli, ML Cosmaro, A Perziano, A Bove, L Taramasso, I Mastrorosa, M Di Gaetano, M Ferrara, M Cernuschi, M Lichtner, A d’Arminio Monforte, A Cingolani, for Icona Foundation Study Group Sexual and reproductive unmet clinical needs in Italian women living with HIV: results from Marilyn study 15° Congresso Nazionale ICAR - Bari, 14-16 Giugno 2023
A. Cozzi-Lepri, A. Tavelli, L. Taramasso, D. Barbanotti , G. Lapadula, N. Bobbio, S. Piconi, G. Guaraldi, A. Di Biagio, C. Muccini, A. Antinori, A. d'Arminio Monforte, on behalf of ICONA Foundation Study group Selected comorbidities and the risk of ART switch in the context of HIV-RNA suppressed to ≤50 copies/mL 15° Congresso Nazionale ICAR - Bari, 14-16 Giugno 2023
R Gagliardini, A Giacomelli, G Bozzi, A D’Arminio Monforte, A Tavelli, V Mazzotta, E Bruzzesi, A Cervo, A Saracino, C Mussini, E Girardi, A Cozzi-Lepri, A Antinori, on behalf of COVID-19 ICONA study group Impact of COVID-19 pandemic on retention in care of native and migrant PLWH in ICONA Cohort 15° Congresso Nazionale ICAR - Bari, 14-16 Giugno 2023
V Mazzotta, A Tavelli, D Moschese, A Cozzi Lepri, FM Fusco, F Colavita, L Biasioli, A Mondi, F Carletti, A Di Biagio, D Mileto, G Baldin, S Nozza, L Pipitò, D Tesoro, N Sangiovanni, E Nicastri, G Rizzardini, F Maggi, A d'Arminio Monforte, A Antinori, S Lanini Predictors of mpox duration and severity in an Italian multicenter Cohort (Mpox-ICONA) 15° Congresso Nazionale ICAR - Bari, 14-16 Giugno 2023
A Vergori, A Cozzi-Lepri, G Marchetti, A Tavelli, R Gagliardini, G Lapadula, N Caroccia, L Taramasso, AM Azzini, S Lanini, F Ceccherini-Silberstein, M Giannella, E Tacconelli, A d’Arminio Monforte, A Antinori, on behalf of VAX-ICONA Study Group SARS-CoV-2 mRNA vaccination and viro-immunological changes in PLWH 15° Congresso Nazionale ICAR - Bari, 14-16 Giugno 2023
A Saracino, M Ponzano, F Bovis, E Quiros-Roldan, M Fabbiani, N Squillace, S Rusconi, M Ferrara, S Lo Caputo, A Tavelli, A Antinori, A d’Arminio Monforte Reasons for choosing a doravirine (DOR) based versus an INSTI-based regimen in ART-naïve and ART-experienced patients in real-world setting: data from ICONA Cohort 15° Congresso Nazionale ICAR - Bari, 14-16 Giugno 2023
A Saracino, M Ponzano, F Bovis, E Quiros-Roldan, M Fabbiani, N Squillace, S Rusconi, M Ferrara, S Lo Caputo, A Tavelli, A Antinori, A d’Arminio Monforte Effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically suppressed persons living with HIV (PLWH): 96-week data from ICONA Cohort 15° Congresso Nazionale ICAR - Bari, 14-16 Giugno 2023
P Piselli, A De Vito, A Tavelli, C Cimaglia, A Nappo, M Farinella, L Rancilio, L Cosmaro, C Muccini, C Santoro, D Segala, M Trizzino, A Caraglia, A d’Arminio Monforte, A Antinori, E Girardi, G Madeddu, for ICONA Foundation Study Group and for the Working Group of the project “The impact of COVID-19 on the processes and outcomes of care of people with HIV” Impact of COVID-19 in time to linkage to care (LtC) and ART initiation in ICONA Cohort 15° Congresso Nazionale ICAR - Bari, 14-16 Giugno 2023
A Giacomelli, R Gagliardini, A Tavelli, S De Benedittis, V Mazzotta, G Rizzardini, A Mondi, D Barbanotti, S Antinori, A Vergori, A Gori, M Menozzi, L Taramasso, FM Fusco, A De Vito, G Mancarella, G Marchetti, A d’Arminio Monforte, A Antinori, A Cozzi-Lepri, on behalf of COVID-19 ICONA study group Risk of COVID-19 in-hospital mortality in people living with HIV compared to general population according to age and CD4 strata: data from ICONA network 15° Congresso Nazionale ICAR - Bari, 14-16 Giugno 2023
A Tavelli, L Cosmaro, N Gianotti, R Gagliardini, VG Calvino, F Bai, G Guaraldi, F Vichi, I Fanti, M Cernuschi, A Antinori, A d’Arminio Monforte, A Cingolani Implementing an Electronic Patient-Reported Outcomes (ePROs) system in PLWH management: experience of Icona Cohort 15° Congresso Nazionale ICAR - Bari, 14-16 Giugno 2023
M Puoti, R Salpini, A Tavelli, L Piermatteo, S D'Anna, S Carrara, V Malagnino, V Mazzotta, G Brancaccio, GB Gaeta, G Marchetti, E Rosselli Del Turco, CF Perno, V Svicher, A d'Arminio Monforte, for Icona Foundation Study Group Prevalence and outcome of Hepatitis Delta virus (HDV) infection among Persons Living with HIV (PLWH) in Italy: the Delta-Icona study 15° Congresso Nazionale ICAR - Bari, 14-16 Giugno 2023
A Vergori, N Gianotti, A Tavelli, C Tincati, A Giacomelli, E Matteini, G Lapadula, F Bai, L Sarmati, A d'Arminio Monforte, A Antinori, A Cozzi-Lepri, on behalf of ICONA Foundation Study Group Probability of starting 2DR vs 3DR regimens in ART-naïve and ART-experienced PLWH before and after the COVID-19 pandemic 15° Congresso Nazionale ICAR - Bari, 14-16 Giugno 2023
A Bove, M Cernuschi, A Cervo, C Pinnetti, A Perziano, M Errico, GV Calvino, M Giglia, M Guastavigna, D Canetti, A Di Biagio, ML Cosmaro, A Cingolani, for Icona Foundation Study Group Quality of pre-and post-COVID-19 healthcare: the point of view of women living with HIV 15° Congresso Nazionale ICAR - Bari, 14-16 Giugno 2023
A Cozzi-Lepri, A Tavelli, L Taramasso, D Barbanotti, G Lapadula, N Bobbio, S Piconi, G Guaraldi, A Di Biagio, A Castagna, A Antinori, A d'Arminio Monforte on behalf of the Icona Foundation Study group Selected comorbidities and the risk of ART switch in the context of HIV-RNA suppressed to ≤50 copies/mL 12th IAS Conference on HIV Science, 23-26 luglio 2023 (EPB0169)
M Puoti, R Salpini, A Tavelli, L Piermatteo, S D'Anna, S Carrara, V Malagnino, V Mazzotta, G Brancaccio, G B Gaeta, G Marchetti, P Viale, C F Perno, V Svicher, A d'Arminio Monforte Hepatitis Delta Virus (HDV) infection: frequency and outcome in Persons Living With HIV (PLWH). Data from the ICONA (Italian Cohort of Naïve for Antiretrovirals) cohort EASL Congress, Vienna, 21 - 24 Giugno 2023
A d'Arminio Monforte, A Tavelli, R Rossotti, R Gagliardini, A Saracino, S Lo Caputo, M Sala, E Quiros Roldan, C Mussini, E Girardi, A Antinori, M Puoti HCV elimination in persons living with HIV (PLWH): the NoCo (No-Coinfection) study of the ICONA network EASL Congress, Vienna, 21 - 24 Giugno 2023
V Mazzotta, A Tavelli, F Colavita, L Biasioli, A Castagna, A Mondi, F Carletti, D Moschese, L Pipitò, D Tesoro, R Gagliardini, F Maggi, A Antinori, A D'Arminio Monforte, S Lanini CLINICAL PREDICTORS OF MPOX SEVERITY IN AN ITALIAN MULTICENTER COHORT (MPOX-ICONA) 30th Conference on Retroviruses and Opportunistic Infections CROI - Seattle, Washington, 19 - 22 Febbraio 2023

2022

Poliseno M, Lo Caputo S, Tavelli A, Gagliardini R, Gazzola L, Saracino A, Santantonio TA, Squillace N, Puoti M, Cicalini S, Antinori A, d'Arminio Monforte A, Cozzi-Lepri A Liver enzymes levels, metabolic and renal profile modifications after switching from TDF- to TAF- based regimens among ART experienced PLWH in the ICONA cohort HIV 2022 - Glasgow, 23 - 25 ottobre 2022
Gagliardini R, Tavelli A, Rusconi S, Lo Caputo S, Spagnuolo V, Santoro M, Costantini A, Cicalini S, Maggiolo F, Giacomelli A, Burastero G, Agrati C, Madeddu G, Quiros Roldan E, d’Arminio Monforte A, Antinori A, Cozzi-Lepri A Characterization and outcomes of difficult to treat patients in an Italian cohort of PLWH starting modern ART regimens HIV 2022 - Glasgow, 23 - 25 ottobre 2022
Malagnino V, Cozzi-Lepri A, Svicher V, Girardi E, Perno CF, Saracino A, Cuomo G, Rusconi S, Puoti M, d'Arminio Monforte A, Andreoni M, Sarmati L for the ICONA Foundation Study Group Coinfection with Hepatitis B Virus and/or Hepatitis C Virus is a risk factor for HIV virological rebound after achieving virological suppression on first ART: results from ICONA cohort HIV 2022 - Glasgow, 23 - 25 ottobre 2022
Saltini P, Cozzi-Lepri A, Bozzi G, Marchetti G, Taramasso L, Mazzanti S, Rizzo V, Antinori A, Mussini C, Gori A, d'Arminio Monforte A, Bandera A Pre-ART platelet-to-lymphocyte ratio and the risk of serious non-AIDS-events, AIDS-events and mortality in PLWH starting first-line ART HIV 2022 - Glasgow, 23 - 25 ottobre 2022
Vergori A, Cozzi-Lepri A, Tavelli A, Giannella M, Cicalini S, Marconi L, Yellenki V, Meschi S, Pellicanò G, Carroccia N, Matusali G, Latini A, Lichtner M, Lo Caputo S, Fusco FM, Marchetti G, Tacconelli E, Antinori A, d'Arminio Monforte A for the VAXICONA-ORCHESTRA Study Group Humoral immunogenicity to third dose SARS-COV-2 mRNA vaccine in people living with HIV (PLWH) by current CD4 count and CD4/CD8 ratio HIV 2022 - Glasgow, 23 - 25 ottobre 2022
d'Arminio Monforte A, Tavelli A, Cingolani A, Taramasso L, Mussini C, Piconi S, Calcagno A, Orofino G, Cicalini S, Castagna A, Ceccherini-Silberstein F, Gori A, Guaraldi G, Antinori A Effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as switch strategy in virologically suppressed: real-world data from the ICONA cohort HIV 2022 - Glasgow, 23 - 25 ottobre 2022
Tavelli A, Marchetti G, Vergori A, Quiros-Roldan E, Malagnino V, Vichi F, Lichtner M, Nozza S, Rossotti R, Sarmati L, Bai F, Di Biagio A, Antinori A, d'Arminio Monforte A Effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in ART-naive patients: real-world data from the ICONA cohort - HIV 2022 - Glasgow, 23 - 25 ottobre 2022
R Salpini, S D’Anna, M Alkhatib, L Piermatteo, A Tavelli, E Quiros-Roldan, A Cingolani, C Papalini, S Carrara, M Puoti, L Sarmati, A d’Arminio Monforte, F Ceccherini Silberstein, CF Perno, V Svicher for the Icona Foundation Study Group In The Setting Of HIV-infection, HBV-reactivation Is Revealed By Highly Sensitive Assays In A Conspicuous Fraction Of Anti-HBc-positive/HBsAg-negative Patients Switching To Tenofovir-sparing Therapy EASL International Liver Congress - Londra, 22 – 26 Giugno 2022 - THU381
R Salpini, S D’Anna, M Alkhatib, L Piermatteo, A Tavelli, E Quiros, A Cingolani, C Papalini, S Carrara, V Malagnino, M Puoti, L Sarmati, A d’Arminio Monforte, F Ceccherini Silberstein, V Svicher for the Icona Foundation Study Group Reactivation of hepatitis B virus is a frequent event in anti-HBc-positive/HBsAg-negative HIV-infected patients switching to Tenofovir sparing therapy as revealed by highly sensitive HBV assays 14° Congresso Nazionale ICAR – Bergamo, 14 - 16 Giugno 2022
P Saltini, A Cozzi-Lepri, G Bozzi, G Marchetti, L Taramasso, S Mazzanti, V Rizzo, A Antinori, C Mussini, A Gori, A d'Arminio Monforte, A Bandera for Icona Foundation Study Group Pre-ART platelet-to-lymphocyte ratio and the risk of serious non-AIDS-events, AIDS-events and mortality in PLWH starting first-line ART 14° Congresso Nazionale ICAR – Bergamo, 14 - 16 Giugno 2022
A d'Arminio Monforte, A Tavelli, A Cingolani, C Mussini, S Piconi, A Calcagno, G Orofino, S Cicalini, A Castagna, F Ceccherini Silberstein, A Gori, A Antinori for Icona Foundation Study Group Real-world effectiveness of switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in women living with HIV: subgroup analysis from ICONA-BIC 14° Congresso Nazionale ICAR – Bergamo, 14 - 16 Giugno 2022
G Lapadula, A Soria, G Micheli, MV Cossu, A De Vito, G Guaraldi, A Castagna, A Di Biagio, S Cicalini, P Bonfanti, A Cozzi-Lepri, A d’Arminio Monforte for Icona Foundation Study Group Treatment with integrase inhibitors among antiretroviral naïve patients is not associated with increased risk of diabetes mellitus 14° Congresso Nazionale ICAR – Bergamo, 14 - 16 Giugno 2022
A d’Arminio Monforte, A Navarra, A Tavelli, B Suligoi, V Regine, L Pugliese, L Timelli, A Caraglia, M Oldrini, L Cosmaro, D Calzavara, M Cernuschi, G Rizzardini, A Gori, S Antinori, M Puoti, A Castagna, E Girardi for Icona Foundation and ISS-COA Group The Cascade of HIV Care (CoC) of Milan as compared to Italy: data derived from the COA Registry and the Icona cohort- Milan Fast Track City 14° Congresso Nazionale ICAR – Bergamo, 14 - 16 Giugno 2022
R Gagliardini, A Tavelli, S Rusconi, A Costantini, S Cicalini, F Maggiolo, V Spagnuolo, E Quiros Roldan, S Lo Caputo, A d'Arminio Monforte, A Antinori, A Cozzi-Lepri for Icona Foundation Study Group Clinical and virological outcomes of difficult to treat patients in a large cohort of PLWH starting modern ART regimens 14° Congresso Nazionale ICAR – Bergamo, 14 - 16 Giugno 2022
A Cingolani, A Tavelli, V Calvino, L Cosmaro, F Bai, C Pinnetti, D Tesoro, F Castelli, F Maggiolo, A Antinori, M Cernuschi, A d'Arminio Monforte for Icona Foundation Study Group Determinants of non disclosure of HIV status in PLWHIV to other than health care workers 14° Congresso Nazionale ICAR – Bergamo, 14 - 16 Giugno 2022
R Gagliardini, A Cozzi-Lepri, A Tavelli, S Rusconi, V Spagnuolo, A Giacomelli, G Burastero, C Agrati, MM Santoro, G Madeddu, A d'Arminio Monforte, A Antinori for Icona Foundation Study Group PLWH with advanced HIV disease are at higher risk for becoming difficult to treat: data from a large cohort of PLWH starting modern ART regimens 14° Congresso Nazionale ICAR – Bergamo, 14 - 16 Giugno 2022
M Poliseno, S Lo Caputo, A Tavelli, R Gagliardini, L Gazzola, A Saracino, TA Santantonio, M Puoti, S Cicalini, A Antinori , A d'Arminio Monforte, A Cozzi-Lepri for Icona Foundation Study Group Liver enzymes levels, metabolic and renal profile modifications after switching from TDF to TAFbased regimens among ART experienced PLWH in ICONA cohort 14° Congresso Nazionale ICAR – Bergamo, 14 - 16 Giugno 2022
A Tavelli, G Marchetti, A Vergori, E Quiros-Roldan, V Malagnino, F Vichi, M Lichtner, S Nozza, R Rossotti, L Sarmati, A Antinori, A d'Arminio Monforte for Icona Foundation Study Group BIC/FTC/TAF in ART-naïve key populations: real-life data from the Icona cohort 14° Congresso Nazionale ICAR – Bergamo, 14 - 16 Giugno 2022
A Tavelli, D Tomasoni, N Gianotti, R Gagliardini, E Bruzzesi, P Milini, B Menzaghi, G Lapadula, P Cinque, L Taramasso, A Antinori, A d'Arminio Monforte for Icona Foundation Study Group Reasons for choosing DRV/cob/FTC/TAF in ART-naïve and ART-experienced patients: data from the Icona Cohort 14° Congresso Nazionale ICAR – Bergamo, 14 - 16 Giugno 2022
A Antinori, A Cozzi-Lepri, A Vergori, A Tavelli, M Giannella, S Cicalini, L Marconi, V Yellenki, S Meschi, G Pellicanò, N Carroccia, G Matusali, A Latini, M Lichtner, S Lo Caputo, FM Fusco, G Marchetti, E Tacconelli, A d'Arminio Monforte for the VAXICONA-ORCHESTRA Study Group Humoral immunogenicity to SARS-CoV-2 mRNA vaccine third additional/booster shot in people living with HIV (PLWH) by current CD4 count 14° Congresso Nazionale ICAR – Bergamo, 14 - 16 Giugno 2022
A Vergori, A Cozzi-Lepri, M Giannella, A Tavelli, AM Azzini, L Marconi, S Cicalini, A Rodanò, S Meschi, M Fusto, A Sartor,G Matusali, S Piconi7, G Pellicano, A Cascio, G Levy-Hara, A Costantini, G Madeddu, G Marchetti, P Viale, E Tacconelli, A d'Arminio Monforte, A Antinori for the VAXICONA-ORCHESTRA Study Group Poor humoral immunogenicity to SARS-CoV-2 vaccination in people living with HIV (PLWH) with low CD4 count 14° Congresso Nazionale ICAR – Bergamo, 14 - 16 Giugno 2022
A Antinori, A Cozzi Lepri, A Vergori, A Tavelli, L Marconi, S Cicalini, AM Azzini, A Sartor, A Rodanò, S Meschi, C Agrati, FM Fusco, E Righi, F Abrizzani, G Marchetti, E Girardi, P Viale, M Giannella, E Tacconelli, A d'Arminio Monforte for the VAXICONA-ORCHESTRA Study Group Poor humoral immunogenicity to SARS-CoV-2 vaccination in people living with HIV (PLWH) with low CD4 count 32nd ECCMID European Congress of Clinical Microbiology & Infectious Diseases – Lisbona, 23 – 26 Aprile 2022
A Tavelli, S Cicalini, D Barbanotti, S Antinori, D Segala, G Guaraldi, M Guastavigna, C Lazzaretti, M Puoti, F Ceccherini Silberstein, A Castagna, E Girardi, A d'Arminio Monforte, A Antinori for Icona Foundation Study Group Proportion Of Plwh Not Vaccinated For Covid-19 In Italy And Predictors CROI 2022, Conference on Retroviruses and opportunistic Infections - Denver, Colorado (USA), 12 - 16 Febbraio 2022

2021

N Gianotti, A Tavelli, A Antinori, F Maggiolo, G Madeddu, A Saracino, S Bonora, L Taramasso, R Gagliardini, G Lapadula, A Cozzi-Lepri, A d’Arminio Monforte Are patients starting first-line ART with a 2-drug regimen (2DR) with dolutegravir/lamivudine different from those initiating 3-drug regimens (3DR) based on an integrase strand transfer inhibitor (InSTI), plus tenofovir alafenamide/emtricitabine? 11th IAS Conference on HIV Science, 18-21 luglio 2021 (PEB145 pag. 148/455)
G Madeddu, A De Vito, A Cozzi-Lepri, A Cingolani, N Gianotti, R Gagliardini, G Marchetti, M Santoro, F Maggiolo, E. Girardi, A d’Arminio Monforte, A Antinori Low risk of losing the undetectable viral load status in people with HIV switching to dual therapy 11th IAS Conference on HIV Science, 18-21 luglio 2021 (PEB165 pag. 158/455)
A Antinori, A Tavelli, C Mussini, A Gori, F Maggiolo, A Castagna, F Ceccherini-Silberstein, S Lo Caputo, M Puoti, C Pinnetti, V Calvino, E Girardi, C F. Perno, A d'Arminio Monforte, A Cozzi-Lepri Impact of lockdown restrictions due to COVID-19 pandemic on HIV care in Italy Virtual CROI 2021, Conference on Retroviruses and opportunistic Infections, 6-10 marzo 2021
V Malagnino, A Cozzi-Lepri, V Svicher, E Girardi, CF Perno, A Saracino, G Cuomo, S Rusconi, M Puoti, A d'Arminio Monforte, M Andreoni, L Sarmati for the ICONA Foundation Study Group Coinfection with Hepatitis B Virus and/or Hepatitis C Virus is a risk factor for HIV virological rebound in course of antiretroviral therapy 13° Congresso Nazionale ICAR - Riccione, 21 - 23 Ottobre 2021
A Cingolani, A Tavelli, F Maggiolo, V Calvino, A Di Biagio, AM Cattelan, L Sighinolfi, G Marchetti, S Nozza, R Rossotti, A d’Arminio Monforte, A Antinori, on behalf of Icona Network Correlates of treatment and disease burden in PLWH in Italy 13° Congresso Nazionale ICAR - Riccione, 21 - 23 Ottobre 2021
F Bai, A Tavelli, A Cozzi-Lepri, M Hadla, S Cicalini, D Vincenti, E Quiros Roldan, E Schiaroli, P Meraviglia, L Taramasso, G Guaraldi, A d’Arminio Monforte, G Marchetti, N Gianotti Associations between weight changes and plasmatic pro-inflammatory cytokines in PLWH following ART initiation: data from the ICONA cohort 13° Congresso Nazionale ICAR - Riccione, 21 - 23 Ottobre 2021
A Cozzi-Lepri, A Vergori, S Lo Caputo, A Cingolani, F Ceccehrini-Silberstein, R Gagliardini, M Lichtner, A Calcagno, G Madeddu, A Castagna, A d’Arminio Monforte, A Antinori on behalf of the Icona Foundation Study cohort Effectiveness of lamivudine + dolutegravir (3TC+DTG) in persons living with HIV (PLWH) starting their first antiretroviral treatment 13°Congresso Nazionale ICAR - Riccione, 21 - 23 Ottobre 2021
A Vergori, A Cozzi-Lepri, A Tavelli, S Lo Caputo, E Quiros-Roldan, G De Girolamo, F Bai, C Mussini, A Di Biagio, L Sarmati, A Antinori, A d’Arminio Monforte for Icona Foundation Study Group Reasons for choosing a TAF-based 3DR instead of a DTG-based 2DR as ART swich strategy for virologically suppressed PLWH in Italy 13° Congresso Nazionale ICAR - Riccione, 21 - 23 Ottobre 2021
S Lo Caputo, A Tavellli, R Gagliardini, S Rusconi, G Lapadula, A Antinori, D Francisci, L Sarmati, A Gori, F Ceccherini-Silberstein, A d'Arminio Monforte, A Cozzi-Lepri on behalf of Icona Foundation Study Group Prevalence, characteristics and outcome of Heavily treated experienced (HTE) HIV-infected patients: data from the Italian ICONA Cohort 13° Congresso Nazionale ICAR - Riccione, 21 - 23 Ottobre 2021
A d’Arminio Monforte, A Tavelli, F Maggiolo, A Castagna, F Ceccherini Silbertein, A Cozzi-Lepri, E Girardi, S Lo Caputo, C Mussini, M Puoti, A Gori, A Antinori for Icona Foundation Study Group BIC/FTC/TAF is effective on PLWH with low CD4 counts: real-life data from the Icona cohort 13° Congresso Nazionale ICAR - Riccione, 21 - 23 Ottobre 2021
A Cingolani, A Tavelli, F Maggiolo, A Perziano, A Saracino, F Vichi, M Cernuschi, G Guaraldi, E Quiros Roldan, A Castagna, A Antinori, A d’Arminio Monforte on behalf of Icona Network Interest in injecting Long-Acting agents by people living with HIV in Italy: a picture from the Icona Network 13° Congresso Nazionale ICAR - Riccione, 21 - 23 Ottobre 2021
L Timelli, A Navarra, P Piselli, V Regine, A Mammone, A Caraglia, L Pugliese, M Oldrini, L Rancilio, L Cosmaro, M Farinella, A Tavelli, A d'Arminio Monforte, B Suligoi, E Girardi Estimation of the proportion of people living with HIV in ART and virally suppressed, using surveillance and cohort data. Italy, 2012-2019 13° Congresso Nazionale ICAR - Riccione, 21 - 23 Ottobre 2021
A Cingolani, A Tavelli, F Maggiolo, A Perziano, A Saracino, F Vichi, M Cernuschi, G Guaraldi, E Quiros Roldan, A Castagna, A Antinori, A d’Arminio Monforte on behalf of Icona Network Understanding PLWH interest in injecting Long-Acting agents. An Italian picture 18th European AIDS Conference, 27-30 October 2021 London, PE7/29

2020

E Merlini, P Lorenzini, C Mussini, A Cozzi-Lepri, S Truffa, E Quiros Roldan, C Muccini, E S Cannizzo, M Lichtner, A Antinori, A d'Arminio Monforte, G Marchetti Residual Inflammation and CD4/CD8 Recovery After Switching to Dual Therapy 12° Congresso Nazionale ICAR, 12 - 16 ottobre 2020
A d'Arminio Monforte, A Tavelli, A Cozzi-Lepri, A Vergori, E Quiros-Roldan, R Rossotti, B M Celesia, F Bai, F Maggiolo, E Girardi, A Antinori, M Puoti Decrease of prevalence of subjects harboring replicating HCV among PLWHIV in Italy: results from the NoCo study 12° Congresso Nazionale ICAR, 12 - 16 ottobre 2020
A Giacomelli, A Cozzi-Lepri, A Cingolani, A Tavelli, V Mazzotta, D Tesoro, M Bassetti, A Castagna, A Di Biagio, M Lichtner, A d'Arminio Monforte, S Rusconi Impact of syphilis on the risk of HIV positive patients under effective antiretroviral treatment: data from the ICONA cohort 12° Congresso Nazionale ICAR, 12 - 16 ottobre 2020
A Vergori, A Cozzi-Lepri, N Gianotti, A Calcagno, G Guaraldi, G Orofino, M C Moioli, I Gentile, L Sarmati, S Cicalini, A d'Arminio Monforte, A Antinori Durability of F/TAF regimens in the era of integrase inhibitors in a large cohort of PLWH seen for care in Italy 12° Congresso Nazionale ICAR, 12 - 16 ottobre 2020
A Saracino, P Lorenzini, M M Santoro, A Tavelli, S Rusconi, N Bobbio, A Mondi, S Lo Caputo, A Antinori, E Girardi, A d'Arminio Monforte, L Monno Post-migration HIV infection in the foreign-born population enrolled in the ICONA cohort 12° Congresso Nazionale ICAR, 12 - 16 ottobre 2020
C Alteri, A Cozzi-Lepri, R Scutari, Y Bouba, E S Cannizzo, A Tavelli, M Prato, F Bai, A Antinori, A d'Arminio Monforte, F Ceccherini-Silberstein, G Marchetti Stable total HIV-DNA after 1 year on switch to TAF-based regimens in real world data 12° Congresso Nazionale ICAR, 12 - 16 ottobre 2020
V Mazzotta, P Lorenzini, A Bandera, A Gori, L Sighinolfi, S Rusconi, P Bonfanti, A Cingolani, G Marchetti, C Mussini, A d'Arminio Monforte, A Antinori Risk of multiple primary neoplasms and impact on survival of person living with HIV (PLWH) 12° Congresso Nazionale ICAR, 12 - 16 ottobre 2020
E S Cannizzo, A Cozzi-Lepri, F Ceccherini S, R Scutari, C Alteri, A Tavelli, D Bernacchia, E Merlini, A Castagna, A Antinori, A d’Arminio Monforte, G Marchetti Reduced Bone catabolism and inflammation in patients switching TAF-containing cART 12° Congresso Nazionale ICAR, 12 - 16 ottobre 2020
S Nozza, L Timelli, A Saracino, N Gianotti, C Lazzaretti, A Tavelli, M Puoti, S Lo Caputo, A Antinori, A d'Arminio Monforte, C Mussini, E Girardi Causes and incidence of hospitalization in patients enrolled in the ICONA cohort 12° Congresso Nazionale ICAR, 12 - 16 ottobre 2020
S Cicalini, P Lorenzini, A Di Biagio, L Taramasso, A Cozzi-Lepri, D Canetti, A Saracino, G Lapadula, R Rossotti, G Guaraldi, G Madeddu, A d'Arminio Monforte, A Antinori Risk of weight gain (WG) according to type of switching strategy in a large cohort of HIV-infected individuals with stable suppressed HIV-RNA 12° Congresso Nazionale ICAR, 12 - 16 ottobre 2020
S Cicalini, P Lorenzini, A Di Biagio, L Taramasso, A Cozzi-Lepri, D Canetti, A Saracino, G Lapadula, R Rossotti, G Guaraldi, G Madeddu, A d'Arminio Monforte, A Antinori Risk of weight gain (WG) according to type of switching strategy in a large cohort of HIV-infected individuals with stable suppressed HIV-RNA IAS Annual Meeting 2020, 11 - 15 ottobre 2020
S Nozza, L Timelli, A Saracino, N Gianotti, C Lazzaretti, A Tavelli, M Puoti, S Lo Caputo, A Antinori, A d'Arminio Monforte, C Mussini, E Girardi Causes and incidence of hospitalization in patients enrolled in the ICONA cohort IAS Annual Meeting 2020, 11 - 15 ottobre 2020
R Gagliardini, A Cozzi Lepri, M Zazzi, A Tavelli, MM Santoro, D Armenia, A Castagna, Gennari, S Rusconi, C Mussini, Laghetti, CF Perno, a D'Arminio, A Antinori Impact of multi-drug resistance on mortality: a multi-cohort Italian study HIV 2020 - Glasgow, 5 - 8 ottobre 2020
A Cingolani, A Tavelli, V Calvino, F Maggiolo, E Girardi, A Cozzi Lepri, A Perziano, A Camposeragna, R Gagliardini, S Nozza, A Antinori, A d'Arminio Monforte Awareness and perception of accuracy of the Undetectable=Untransmittable (U=U) message in people living with HIV/AIDS (PLWHA), in Italy and correlation with the level of confidence in reference physicians HIV 2020 - Glasgow, 5 - 8 ottobre 2020
A Vergori, A Cozzi Lepri, N Gianotti, A Calcagno, G Guaraldi, G Orofino, MC Moioli, I Gentile, L Sarmati, S Cicalini, A d'Arminio Monforte, A Antinori Durability of F/TAF in a large cohort of PLWH seen for care in Italy HIV 2020 - Glasgow, 5 - 8 ottobre 2020
R Rossotti, A Tavelli, MG Quaranta, L Ferrigno, F Bai, F Barbaro, A Cingolani, M Dallio, M Loi, E Zappullo, A d'Arminio Monforte, M Puoti HIV/HCV co-infected sujects show better thrombocytopenia improvement after Sustained Virologic Response than HCV mono-infected cirrhotics. Data from the HepaICONA and PITER cohorts EASL International Liver Congress, 27 - 29 agosto 2020
A Antinori, F Maggiolo, N Gianotti, S R Cole, J K Edwards, S Lo Caputo, A Calcagno, D Francisci, P Blanc, C Mussini, A d'Arminio Monforte, A Cozzi-Lepri Emulation of an RCT of dolutegravir vs. boosted-darunavir in advanced ART-naive CROI - Conference on Retroviruses and Opportunistic Infections - Boston, 8 - 11 marzo 2020
G Madeddu, A De Vito, A Cozzi-Lepri, A Cingolani, F Maggiolo, C F Perno, R Gagliardini, G Marchetti, A Saracino, A d'Arminio Monforte, A Antinori, E Girardi Implementation of U=U in real life in Italy: results fron the ICONA cohort CROI - Conference on Retroviruses and Opportunistic Infections - Boston, 8 -11 marzo 2020
R Gagliardini, P Lorenzini, A Cozzi-Lepri, A Tavelli, V Borghi, L Galli, G Tagliaferri, F Maggiolo, C Mussini, A Castagna, A d'Arminio Monforte, A Antinori Effect of past virological failure on dolutegravir+lamivudine as manteinance regimen CROI - Conference on Retroviruses and Opportunistic Infections - Boston, 8 - 11 marzo 2020
L Fabeni, M M Santoro, P Lorenzini, S Rusconi, N Gianotti, A Costantini, L Sarmati, A Antinori, F Ceccherini Silberstein, A d'Arminio Monforte, A Saracino, E Girardi Evaluation of HIV transmission clusters among natives and foreigners living in Italy CROI - Conference on Retroviruses and Opportunistic Infections - Boston, 8 - 11 marzo 2020
A Mondi, P Lorenzini, A Cozzi-Lepri, A Cingolani, M Farenga, S Rusconi, G De Girolamo, A Gori, M Camici, C Mussini, A d'Arminio Monforte, A Antinori Persistent poor clinical outcomes for AIDS presentation in Italy over the last decade CROI - Conference on Retroviruses and opportunistic Infections - Boston, 8 - 11 marzo 2020
A Bandera, A Cozzi-Lepri, A Cingolani, F Ceccherini-Silberstein, G Marchetti, S Rusconi, V Svicher, R Cauda, F Castelli, A Gori, A Antinori, A d'Arminio Monforte Impact of universal ART access on Kaposi Sarcoma burden: results from the ICONA cohort CROI - Conference on Retroviruses and Opportunistic Infections - Boston, 8 -11 marzo 2020

2019

R. Rossotti, G. Guaraldi, A. Cozzi Lepri, V. Spagnuolo, S. Cicalini, J. Vecchiet, E. Quiros Roldan, G. Madeddu, S. Lo Caputo, A. Antinori, M. Puoti, A. d’Arminio Monforte on behalf of the ICONA Foundation Study Group. Low Body Mass Index (BMI) in ART naïve HIV-positive subjects and risk of virologic failure and drug discontinuation: data from the ICONA Foundation cohort. The 17th European AIDS Conference (EACS 2019), November 6 - 9, 2019. Basel, Switzerland.
R Rossotti, A Saracino, P Lorenzini, C Alcantarini, A Latini, G Lapadula, S Nozza, L Sarmati, E Girardi, A Castagna, A d’Arminio Monforte, M Puoti on behalfof the ICONA Foundation StudyGroup. Long term response to mandatory anti-HBV vaccination: risks for disease acquisition and opportunities for re-vaccination within the ICONA cohort. The 17th European AIDS Conference (EACS 2019), November 6 - 9, 2019. Basel, Switzerland.
A. d’Arminio Monforte, A. Tavelli, A. Cozzi-Lepri, S. Cicalini, A. Calcagno, R. Rossotti, E. Grilli, F. Bai, E. Quiros-Roldan, E. Girardi, A. Antinori, M. Puoti, for the NoCo Study of the Icona cohort. Road to hcv elimination in hiv/hcv coinfected patients by screening and universal access to daa: baseline data from the first screening of noco (no coinfection) study. The 17th European AIDS Conference (EACS 2019), November 6 - 9, 2019. Basel, Switzerland.
A. Mondi, A. Cozzi-Lepri, A. Cingolani, A. Tavelli, M. Puoti, V. Barocci, A. Londero, F. Bai, C. Pinnetti, P. Cinque, A. d’Arminio Monforte8, A. Antinori on behalf of the Icona Foundation Study Group. Comparative neuropsychiatric toxicity profile of dolutegravir versus efavirenz versus other antiretroviral third drugs used either in first-line or switch antiretroviral therapies (art): data from icona foundation study cohort. The 17th European AIDS Conference (EACS 2019), November 6 - 9, 2019. Basel, Switzerland.
A Antinori, A Mondi, P Lorenzini, A Cozzi-Lepri, A Cingolani, F Maggiolo, A Saracino, A Bandera, G Marchetti, C Mussini, E Girardi, A d’Arminio Monforte. Change of prevalence, diseases distribution and factors associated with the risk of AIDS presentation in Italy over last decade (2009-2018). The 17th European AIDS Conference (EACS 2019), November 6 - 9, 2019. Basel, Switzerland.
A Gabrieli, L Galli, M Tarkowski, C De Giuli, A Saracino, G Marchetti, S Bonora, E Lattuada, M Mena, A d'Arminio Monforte, A Castagna, A Riva, S Rusconi on behalf of ICONA Foundation and ELVIS cohort. HIV-DNA LEVELS, HLA-B*27 and HLA-DRB1*13 AMONG LTNPs, ECs and HIV controllers. The 17th European AIDS Conference (EACS 2019), November 6 - 9, 2019. Basel, Switzerland.
A Vergori, R Gagliardini, N Gianotti, A Gori, M Lichtner, A Saracino, A De Vito, A Cascio, A di Biagio, A d’Arminio Monforte, A Antinori, A Cozzi-Lepri on behalfof ICONA Foundation StudyGroup. Determinants of switchingto TAF-basedcARTor dualcombinations(DC) from TDF-basedregimensin a cohort of HIV-infectedindividualswith controlledviralload≤50 copies/mL. The 17th European AIDS Conference (EACS 2019), November 6 - 9, 2019. Basel, Switzerland.
A Cingolani, J Romaine, A Tavelli, F Maggiolo, M Camici, F Bai, S Rusconi, AM Cattelan, A Antinori, R Cauda, A d’Arminio Monforte & C Bradley. Well-being in people living with hiv/aids (plwha): data from icona cohort. The 17th European AIDS Conference (EACS 2019), November 6 - 9, 2019. Basel, Switzerland
C Mussini, P Lorenzini, A Cingolani, M Lichtner, S Di Giambenedetto, AM Cattelan, M Malena, G d’Ettorre, A d’Arminio Monforte. Virological outcomesof first line regimensin womenliving with HIV from Icona cohort: comparisonwith clinicaltrials data. The 17th European AIDS Conference (EACS 2019), November 6 - 9, 2019. Basel, Switzerland
E Merlini, A Cozzi-Lepri, C Alteri, R Scutari, A Cingolani, F Bai, F Petroni, S Lo Caputo, A Antinori, CF Perno, A d'Arminio Monforte, G Marchetti. The 17th European AIDS Conference (EACS 2019), November 6 - 9, 2019. Basel, Switzerland Effect of simplification to INSTI-based dual therapy on residual inflammation and viral reservoir. The 17th European AIDS Conference (EACS 2019), November 6 - 9, 2019. Basel, Switzerland
S. Leone, P. Lorenzini, A. Cozzi-Lepri, G. Orofino, D. Bernacchia, A. Castagna, M. Menozzi, G. Guaraldi, G. Madeddu, A. Di Biagio, A. Gori, A. d'Arminio Monforte, for the ICONA Foundation Cohort Study Serious liver events and liver-related deaths in HIV/HCV co-infected patients with diabetes: data from the ICONA Foundation Cohort Study. 11° Congresso ICAR - Italian Conference on AIDS and Antiviral Research - Milano, 5-7 giugno 2019
A. Antinori, A. Mondi, P. Lorenzini, A. Cozzi-Lepri, A. Cingolani, A. Latini, A. Saracino, A. Bandera, G. Marchetti, C. Mussini, E. Girardi, A. d’Arminio Monforte Change of prevalence and factors associated with the risk of AIDS presentation in Italy over last decade (2009-2018). 11° Congresso ICAR - Italian Conference on AIDS and Antiviral Research - Milano, 5-7 giugno 2019
S. Lo Caputo, A. Antinori, A. Tavelli, F. Ceccherini-Silberstein, C.F. Perno, A. Castagna, N. Bobbio, G. Parruti, R. Gagliardini, S. Bonora, A. d’Arminio Monforte, A. Cozzi Lepri for the ICONA Foundation Study Group Variables related to becoming Heavily Treated Experienced (HTE) patients in a large Italian cohort. 11° Congresso ICAR - Italian Conference on AIDS and Antiviral Research - Milano, 5-7 giugno 2019
A. Antinori, A. Cozzi-Lepri, D. Moschese, S. Nozza, L. Comi, M. Santoro, L. Sarmati, C. Pinnetti, F. Ceccherini Silberstein, G. Marchetti, F. Maggiolo, A. d’Arminio Monforte for the Icona Foundation Study Group Viral potency and durability of emtricitabine/tenofovir alafenamide (F/TAF) based regimens in the real life setting 11° Congresso ICAR - Italian Conference on AIDS and Antiviral Research - Milano, 5-7 giugno 2019
A. Vergori, R. Gagliardini, N. Gianotti, A. Gori, M. Lichtner, A. Saracino, A. De Vito, A. Cascio, A. Di Biagio, A. d’Arminio Monforte, A. Antinori, A. Cozzi- Lepri Determinants of switching to TAF-based cART or dual combinations (DT) from TDF-based regimens in a cohort of HIV-infected individuals with controlled viral load≤50 copies/mL 11° Congresso ICAR - Italian Conference on AIDS and Antiviral Research - Milano, 5-7 giugno 2019
C. Mussini, P. Lorenzini, A. Cingolani, M. Lichtner, S. Di Giambenedetto, A.M. Cattelan, E. Balletto, L. Sighinolfi, C. Abeli, M. Malena, G. d’Ettorre, A. d’Arminio Monforte Virological outcomes of first line regimens in women living with HIV from Icona cohort: comparison with clinical trials data. 11° Congresso ICAR - Italian Conference on AIDS and Antiviral Research - Milano, 5-7 giugno 2019
A. Mondi, P. Lorenzini, A. Cozzi-Lepri, A. Cingolani, M. Farenga, S. Rusconi, G. Di Girolamo, A. Gori, M. Camici, C. Mussini, A. d’Arminio Monforte, A. Antinori1 on behalf of the Icona Foundation Study Cohort Lower response to antiretroviral therapy (ART) and persistently poor survival for AIDS presentation in people seen for care in Italy from 2009 to 2018. 11° Congresso ICAR - Italian Conference on AIDS and Antiviral Research - Milano, 5-7 giugno 2019
E. Suardi, A. Cozzi Lepri, G. Madeddu, V. Spagnuolo, S. Vita, V. Manfrin, A. Bandera, A. Cingolani, A. Antinori, C. Mussini, G. Marchetti, A. d'Arminio Monforte, for the Icona Foundation Study Group CD4/CD8 ratio predicts the onset of virus-related cancers in HIV-positive patients on effective cART. 11° Congresso ICAR - Italian Conference on AIDS and Antiviral Research - Milano, 5-7 giugno 2019
A. d’Arminio Monforte, A. Tavelli, A. Cozzi-Lepri, A. Castagna, S. Passerini, D. Francisci, A. Saracino, F. Maggiolo, G. Lapadula, E. Girardi, C.F. Perno, A. Antinori for the Icona Foundation Study Group Is time from HIV diagnosis to ART initiation predictive of virological outcome and of retention in care? 11° Congresso ICAR - Italian Conference on AIDS and Antiviral Research - Milano, 5-7 giugno 2019
P. Piselli, A. Tavelli, C. Cimaglia, G. Chiaradia, L. Rancilio, M. Oldrini, A. Cingolani, M.E. Quiros Roldan, V. Rizzo, S Rusconi, A. Caraglia, A. d’Arminio Monforte, E. Girardi for the ICONA Foundation Study Group and for the Working Group of the project “Linkage to Care in HIV: a further piece to the analysis of continuum of care in HIV in Italy” Time to Linkage to Care (LtC) in the ICONA COHORT: 2010-2018 11° Congresso ICAR - Italian Conference on AIDS and Antiviral Research - Milano, 5-7 giugno 2019
A. Mondi, A. Cozzi-Lepri, A. Cingolani, A. Tavelli, M. Puoti, V. Barocci, A. Londero, F. Bai, C. Pinnetti, P. Cinque, A. d’Arminio Monforte, A. Antinori on behalf of the Icona Foundation Study Group Comparative neuropsychiatric toxicity profile of dolutegravir (DTG)-based versus efavirenz (EFV)-based versus other recommend first-line antiretroviral therapies (ART): data from Icona Foundation Study Cohort, 11° Congresso ICAR - Italian Conference on AIDS and Antiviral Research - Milano, 5-7 giugno 2019
A. d’Arminio Monforte, A. Tavelli, A. Cozzi-Lepri, S. Cicalini, A. Calcagno, R. Rossotti, E. Grilli, F. Bai, E. Quiros-Roldan, E. Girardi, A. Antinori, M. Puoti for the NoCo Study of the Icona cohort Road to HCV elimination in HIV/HCV coinfected patients by screening and universal access to DAA: baseline data from the first screening of NoCo (No Coinfection) study 11° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Milano, 5-7 giugno 2019
V Malagnino, A Cozzi-Lepri, L Sarmati, A Cingolani, C Cerva, F Ceccherini Silberstein, A Vergori, G Cuomo, CF Perno, M Puoti, M Andreoni, A d'Arminio Monforte, for the ICONA Foundation Study Group. Impact of HBcAb+ on advanced liver fibrosis development in HIV-HBV infected patients. 26th CROI Conference on Retrovirus and Opportunistic Infections. Seattle, March 4-7, 2019
A Mondi, P Lorenzini, A Tavelli, A Cozzi-Lepri, F Maggiolo, N Gianotti, D Francisci, C Carcieri, A De Vito, A Di Biagio, A d'Arminio Monforte, A Antinori, for the ICONA Foundation Study Group. Effectiveness of single- vs multiple-tablet regimens as 1st-line ART in ICONA Cohort. 26th CROI Conference on Retrovirus and Opportunistic Infections. Seattle, March 4-7, 2019
E Girardi, Y Caro-Vega, J Musaazi, G Carriquiry, A Cozzi-Lepri, B Castelnuovo, A Gori, Y C. Manabe, E Gotuzzo, A d'Arminio Monforte, B Crabtree-Ramírez, C Mussini, for the ICoNA Study Group, IMT AvH, INNSZ and IDI Cohorts. Timing and incidence of HIV-associated tuberculosis: a four-country study. Timing and incidence of HIV-associated tuberculosis: a four-country study. 26th CROI Conference on Retrovirus and Opportunistic Infections. Seattle, March 4-7, 2019
V Spagnuolo, L Galli, A Cozzi-Lepri, G Lapadula, A Antinori, G Orofino, N Bobbio, MC Moioli, A Calcagno, A De Luca, A d'Arminio Monforte, A Castagna, for the ICONA Foundation Study Group. Time to undetectable viral load achievement after art start and risk of mortality. 26th CROI Conference on Retrovirus and Opportunistic Infections. Seattle, March 4-7, 2019
R Gagliardini, P Lorenzini, A Cozzi-Lepri, N Gianotti, L Sarmati, S Rusconi, E Messina, A Capetti, A Saracino, G Madeddu, A d'Arminio Monforte, A Antinori, for the ICONA Foundation Study Group. Evolution and reversibility of renal function after switch from TDF to TAF regimens. 26th CROI Conference on Retrovirus and Opportunistic Infections. Seattle, March 4-7, 2019

2018

EM Lori, A Cozzi-Lepri, V Mercurio, SV Ibba, S Lo Caputo, F Castelli, A Castagna, A Gori, G Marchetti, C Venditti, M Clerici, A d’Arminio Monforte, M Biasin. Evaluation of Protective Genetic Variants in HIV-1-Infected cART Treated Patients. HIV Research for Prevention 2018: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P) - Madrid, 21–25 October 2018.
A Vergori, P Lorenzini, A Cozzi-Lepri, F Maggiolo, G Lapadula, A De Luca, A Cingolani, M Galli, G Mazzarello, P Milini, A d’Arminio Monforte, A Antinori on behalf of ICONA Foundation Study Group. Incidence and determinants of antiretroviral switching away from TDF-based backbone in the recent years in the Icona Foundation Cohort. HIV DRUG THERAPY GLASGOW, 28/31 October 2018
A Cozzi-Lepri, A d'Arminio Monforte, A Capetti, A De Luca, A Castagna, D Bernacchia, F Bai, M Zaccarelli, A Cingolani, C Mussin, C F Perno and A Antinori for the Icona Foundation Study. Determinants of switching to taf-based cart or two-drug combinations with hivrna ≤50 copies/ml in a cohort of hiv-infected individuals seen for care in italy. HIV DRUG THERAPY GLASGOW, 28/31 October 2018
G Taliani, G Marchetti, A Cingolani, M Lichtner, S Cicalini, E Quiros Roldan, M Ursitti, E Girardi, A Antinori, M Puoti, A d'Arminio Monforte, A Cozzi-Lepri. Increased total and ldl cholesterol plasma levels upon direct antiviral agents (daas) driven hcv eradication. HIV DRUG THERAPY GLASGOW, 28/31 October 2018
A Calcagno, A Cozzi-Lepri, A Saracino, A De Luca, E Colella, A Cingolani, L Sarmati, F Ceccherini-Silberstein, A Antinori, M Puoti, CF Perno, A d'Arminio Monforte. Long-term Follow up of HIV-HBV Co-infected Patients According to the Use of Anti-HBV Active Drugs. HIV DRUG THERAPY GLASGOW, 28/31 October 2018
A Cozzi-Lepri, H Diaz-Cuervo, N Gianotti, G Lapadula, A De Luca, F Maggiolo, S Rusconi, N Bobbio, V Esposito, MC Moioli, G Madeddu, A Antinori, A d'Arminio Monforte. Determinants of switching to two-drug combinations with hiv-rna ≤50 copies/ml in a cohort of hivinfected individuals seen for care in Italy. HIV DRUG THERAPY GLASGOW, 28/31 October 2018
S Cicalini, P Lorenzini, A Cozzi-Lepri, F Maggiolo, N Gianotti, S Rusconi, G Lapadula, O Cirioni, A Castagna, C Mussini, S Lo Caputo, A Antinori. Incidence of dyslipidemia and modification of atherosclerotic cardiovascular disease (ASCVD) risk in HIV-infected patients who switch away from tenofovir disoproxil fumarate (TDF)-based to TDF-sparing regimens in the Icona Foundation Cohort. HIV DRUG THERAPY GLASGOW, 28/31 October 2018
A Vergori, P Lorenzini, A Cozzi Lepri, F Maggiolo, G Lapadula, A De Luca, A Cingolani, M Galli, G Mazzarello, P Milini, A D'Arminio Monforte, A Antinori. Incidence and determinants of antiretroviral switching away from TDF-based backbone in the recent years in the Icona Foundation Cohort. HIV DRUG THERAPY GLASGOW, 28/31 October 2018
S Vita, P Lorenzini, M Lichtner, G Marchetti, CM Mastroianni, A Bandera, A Di Biagio, C Pinnetti, A Calcagno, A Castagna, A Antinori, A d'Arminio Monforte. Impact of CMV on liver progression in HIV/HCV/CMV coinfected patients in a large cohort of HIV-infected patients. HIV DRUG THERAPY GLASGOW, 28/31 October 2018
A Cingolani, J Romaine, A Tavelli, F Maggiolo, E Girardi, A Antinori, A Cascio, AM Cattelan, A De Luca, M Murray, A D'Arminio Monforte, C Bradley. Health status and Quality of life in people living with HIV (PLWH): results from the ICONA cohort. HIV DRUG THERAPY GLASGOW, 28/31 October 2018
A Tavelli, M Palma, S Lo Caputo, G Madeddu, P Bonfanti, B Menzaghi, S Nozza, A Antinori, R Termini, A d'Arminio Monforte. Reasons for choosing darunavir/ritonavir 600/100 mg BID vs. 800/100 mg QD in ART-naive patients. HIV DRUG THERAPY GLASGOW, 28/31 October 2018
A. Tavelli, A. Cozzi-Lepri, C. Mussini, A. Castagna, A. Saracino, A. Cingolani, B. Menzaghi, G. Lapadula, S. Savinelli, A. Antinori, A. d'Arminio Monforte, M. Puoti. Response to DAA among HIV-HCV co-infected people who inject drugs (PWID) in clinical practice. 10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24 maggio 2018
A. Tavelli, M. Palma, S. Lo Caputo, G. Madeddu, P. Bonfanti, B. Menzaghi, S. Nozza , A. Antinori, R. Termini, A. d’Arminio Monforte. Reasons for choosing darunavir/ritonavir 600/100 mg twice daily vs. 800/100 mg once daily in treatment-naïve patients: 10 years data from the ICONA cohort. 10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24
L. Taramasso, P. Lorenzini, A. Di Biagio, M. Lichtner, G. Marchetti, R. Rossotti, G. Lapadula, D. Minisci, F. Vichi, A. Antinori, S. Bonora, A. d'Arminio Monforte. Liver enzyme elevations according to the first line cART regimen: real life data from the ICONA cohort. 10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24 maggio 2018
A. Cingolani, J. Romaine, A. Tavelli, F. Maggiolo, E. Girardi, A. Antinori, A. Cascio, A.M. Cattelan, A. De Luca, M. Murray, A. d’Arminio Monforte, A. Bradley. Health status and Quality of life in people living with HIV (PLWH): results from the ICONA cohort. 10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24 maggio 2018
A. Cozzi-Lepri, M. Zaccarelli, A. Capetti, A. De Luca, A. Castagna, D. Bernacchia, F. Bai, A. Cingolani, C. Mussini, C.F. Perno, A. d'Arminio Monforte, A. Antinori. Use of TAF with a HIV-RNA≤50 copies/mL in clinical practice. 10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24 maggio 2018
P. Piselli, D. Serraino, A. Bandera, A. Antinori, E. Girardi, C. Cimaglia, A. Tavelli, F. Bai, G. Baldin, A. Calcagno, A. d'Arminio Monforte, A. Cingolani. Non-AIDS related cancer risk is not affected by cART in ICONA cohort. 10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24 maggio 2018.
G. Lapadula, A. d’Arminio Monforte, A. Castagna, S. Rusconi, C. Mussini, E. Colella, A. Gori, C. Fabrizio, V. Spagnuolo, E. Schiaroli, A. Antinori, A. Cozzi-Lepri. HIV viral load kinetcs during first-line antiretroviral treatment and risk of virological non-response or rebound among patient with high pre-treatment HIV-RNA. 10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24 maggio 2018
I. Mastrorosa, P. Lorenzini, A. Cozzi-Lepri, M. Puoti, R. Rossotti, G. Marchetti, G. Orofino, L. Sighinolfi, A. Raimondi, A. d'Arminio Monforte, A. Antinori, A. De Luca. Impact of HCV treatment with Direct-Acting Antivirals on glucose levels in diabetic HIV/HCV co-infected patients in the ICONA and HepaICONA cohorts. 10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24 maggio 2018
E. Girardi , A. Cozzi-Lepri , A. Gori , A Saracino, A Di Biagio, G Lapadula, G Orofino, M Lichtner, S Lo Caputo, A Antinori, A d'Arminio Monforte , C Mussini. Which is the current risk of tuberculosis in persons diagnosed with HIV in Italy? 10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24 maggio 2018
A. Bandera, P. Lorenzini, G. Lapadula, C. Mussini, A. Saracino, F. Ceccherini-Silberstein, M. Puoti, E. Quiros-Roldan, F. Montagnani, A. Antinori, A. Gori, A. d’Arminio Monforte. The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocytes trajectories in HIV/HCV coinfected patients: data from the Icona Foundation Cohort. 10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24 maggio 2018
A. Mondi, A. Cozzi-Lepri, A. Tavelli, S. Rusconi, F. Vichi, B. Menzaghi, F. Ceccherini-Silberstein, A. Calcagno, F. Maggiolo, G.Marchetti, A. Antinori, A. d'Arminio Monforte. Effectiveness of dolutegravir (DTG)-based regimens as either first line or switch antiretroviral therapy (ART): data from the Icona cohort. 10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24 maggio 2018.
I. Mastrorosa, A. Cozzi-Lepri, E. Girardi, A. Calcagno, G. Madeddu, A. Maddaloni, M. Farenga, A. Cristaudo, P. Meraviglia, A. Antinori, A. d'Arminio Monforte, A. Cingolani. Patient-Reported Outcomes (PROs) evaluation among HIV-infected (HIV+) patients (pts) starting elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF). 10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24 maggio 2018
A. d'Arminio Monforte, A. Cozzi-Lepri, S. Lo Caputo, S. Rusconi, N. Gianotti, A. Di Biagio, G. Marchetti, V. Mazzotta, G. Mazzarello, A. Costantini, A. Castagna, A. Antinori. Durability of integrase inhibitors (INSTI) regimens in the clinical setting: data from the Icona Foundation Cohort. 10° Congresso Nazionale ICAR - Italian Conference on AIDS and Antiviral Research - Roma, 22-24 maggio 2018
E Girardi, M Puoti, C Mussini, A Tavelli, I Mastrorosa, F Ceccherini Silberstein, G Madeddu, C Molteni, P Nasta, A Antinori, A d'Arminio Monforte, A Cozzi-Lepri. The Hepatitis C Continuum of Care among HIV infected individuals in the Icona study network. The International Liver Congress 2018 (EASL) – Paris, 11/15 April 2017.
R Rossotti, P Lorenzini, M Merli, A Castagna, A De Luca, A Antinori, M Chiamenti, I Mastrorosa, G Verucchi, F Maggiolo, A d'Arminio Monforte, M Puoti. Genotype 3 infection in HIV/HCV co-infected subjects in the DAA era: real life data from the Icona/Hepaicona foundation cohorts. The International Liver Congress 2018 (EASL) – Paris, 11/15 April 2017.
R Rossotti, A Tavelli, S Bonora, A Cingolani, S Lo Caputo, A Saracino, G Lapadula, L Marinaro, C Uberti-Foppa, C Mussini, M Puoti, A d'Arminio Monforte.s. Safety and Efficacy of Daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: data from the Icona/Hepaicona foundation cohort The International Liver Congress 2018 (EASL) – Paris, 11/15 April 2017.
GB Gaeta, M Shanyinde, G Brancaccio, M Puoti, Ad'Arminio Monforte, A De Luca, A Vergori, S Rusconi, A Mazzarelli, A Castagna, A Antinori, A Cozzi-Lepri. Hepatitis Delta infection in patients with HIV/HBV coinfection. 25th CROI – Conference on Retrovirus and Opportunistic Infections. Boston, March 4-7, 2018
P Piselli , D Serraino , A Bandera , A Antinori , E Girardi , C Cimaglia ,A Tavelli , F Bai , G Baldin , A Calcagno , A d'Arminio Monforte , A Cingolani for the Icona Foundation Study Group. Still high risk of Virus-related cancer despite 20 years of cART in Icona Cohort. 25th CROI – Conference on Retrovirus and Opportunistic Infections. Boston, March 4-7, 2018
E Girardi , A Cozzi-Lepri , A Gori , A Saracino , A Di Biagio , G Lapadula , G Orofino , M Lichtner , S Lo Caputo , A Antinori , A d'Arminio Monforte , C Mussini , for the Icona Foundation Study Group. HIV-associated TB in a low burden country: is screening for latent TB still needed? 25th CROI – Conference on Retrovirus and Opportunistic Infections. Boston, March 4-7, 2018
N Gianotti, P Lorenzini, A Cozzi-Lepri, A De Luca, G Madeddu, L Sighinolfi, C Pinnetti, C Santoro, P Meraviglia, C Mussini, A Antinori, A D'Arminio Monforte. Durability of initial regimens when starting ART with -200 CD4 and +5 Log HIV-RNA. 25th CROI Conference on Retrovirus and Opportunistic Infections. Boston, March 4-7, 2018

2017

A Cingolani, L Galli, G Lapadula, S Bonora, C Uberti Foppa, A Di Biagio, G Verucchi, S Odolini, C Mussini, A Antinori, A d'Arminio Monforte, M Zaccarelli for Icona Foundation Study Group. Evolution of renal function during treatment with direct antiviral agents (DAA-t) in HIV/HCV infected patients in ICONA/HepaIcona cohorts. 16th European AIDS Conference from October 25-27, 2017.
L Galli, A Castagna, A Vergori, G Baldin, N Galizzi, A Poli, E Girardi, MM Santoro, A Saracino, A Cingolani, C Mussini, A Lazzarin, A Antinori, A d’Arminio Monforte. High pre-ART viral load and risk of death in HIV-1 infected subjects: an Italian inter-cohort study. 16th European AIDS Conference from October 25-27, 2017.
A Bandera, A Cozzi Lepri, L Galli, N Galizzi, G Baldin, L Teofili, V Mazzotta, L Alba, A Castagna, A Gori, A d'Arminio Monforte, A Antinori, A Cingolani for the Icona Foundation Study Group. Outcome of HIV-associated non-Hodgkin lymphomas can be predicted by lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio. 16th European AIDS Conference from October 25-27, 2017.
A Mondi, A Cozzi-Lepri, A Tavelli, F Vichi, S Rusconi, T Quirino, F Ceccherini-Silberstein, A Calcagno, F Maggiolo, G Marchetti, A Antinori, A d'Arminio Monforte. Effectiveness and discontinuation rate of dolutegravir (DTG)-based regimensas either first line or switch antiretroviral therapy (ART): data from the Icona cohort. 16th European AIDS Conference from October 25-27, 2017.
B Rossetti, P Lorenzini, A Cingolani, A Tavelli, M Puoti, I Mastrorosa, A Gori, S Lo Caputo, R Rosso, A Antnori, A d’Arminio Monforte, A De Luca on behalf of ICONA Foundation study group. Progression of liver disease, access to HCV treatment with direct acing anIvirals and eradicaIon rate according to sex in HIV/HCV coinfected paIents in Italy. 16th European AIDS Conference from October 25-27, 2017.
A Cozzi-Lepri, M Zaccarelli, S Rusconi, N Gianotti, S Bonora, A De Luca, G Madeddu, N Galizi, VEsposito, M Puoti, A d’Arminio Monforte and A Antinori for the Icona Foundation Study cohort. Two years of exposure to elvitegravir/cobicistat/emtricitabine/tenofovir(E/C/FTC/TDF): an overview of the trend in laboratory parameters in clinical practice. 16th European AIDS Conference from October 25-27, 2017.
A Mammone, A Tavelli, A Costantini, P Caramello, C Mussini, A Di Biagio, G Madeddu, A d’Arminio Monforte, E Girardi for the ICONA Foundation Study Group. Trends and determinants of viral suppression among persons on HIV care in Italy. 9th IAS 2017 conference, 23-26 July, Paris
S Piconi, G Marchetti, A Gori, A Castagna, G Rizzardini, P Caramello, PE Manconi, A d’Arminio Monforte and A Cozzi-Lepri for Icona Foundation Study cohort. HIV-RNA, CD4/CD8 ratio and HDL-c concentration in a cohort of HIV+ ART-naïve patients: data from ICONA Foundation cohort. 9th IAS 2017 conference, 23-26 July, Paris
A Di Biagio, L Taramasso, A Cozzi-Lepri, F Maggiolo, A Tavelli, S Lo Caputo, S Bonora, M Zaccarelli, P Caramello, A Costantini, C Viscoli, A d’Arminio Monforte A comparison of 2-year durability of efavirenz and rilpivirine based regimens in clinical practice: data from the ICONA Foundation cohort (P 97) IX Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Siena 12-14 giugno 2017
A Bandera, A Cozzi Lepri, L Galli, N Galizzi, GM Baldin, L Teofili, V Mazzotta, L Alba, A Castagna, A Gori, A d'Arminio Monforte, A Antinori, A Cingolani for the Icona Foundation Study Group Lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio predict survival in HIV-infected patients with non-Hodgkin lymphomas (PD 12) IX Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Siena 12-14 giugno 2017
A Saracino, M Zaccarelli, P Lorenzini, A Bandera, G Marchetti, F Castelli, A Gori, E Girardi, C Mussini, P Bonfanti, A Ammassari, A d’Arminio Monforte, for the Icona Foundation Study Group Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for HIV-infected people (OC 71) IX Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Siena 12-14 giugno 2017
B Rossetti, P Lorenzini, A Cingolani, A Tavelli, M Puoti, G Cassola, G Angarano, G Taliani, E Girardi, A Antinori, A d’Arminio Monforte, A De Luca Gender differences in HCV exposure, active replication and genotypes in HIV patients entering care in Italy (OC 60) IX Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Siena 12-14 giugno 2017
M Zaccarelli, A Antinori, A Saracino, G Madeddu, G Rizzardini, S Lo Caputo, A Castagna, A Tavelli, A d'Arminio Monforte, A Cozzi-Lepri Value of CD4 count nadir and of time since occurrence of CD4 count nadir to predict viral rebound in a selected population who underwent a therapy switch after achieving viral suppression (OC 19) IX Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Siena 12-14 giugno 2017
C Mussini, P Lorenzini, S Rusconi, G Marchetti, A Gori, S Nozza, MM Santoro, A Calcagno, A Saracino, M Lichtner, A Antinori, A d'Arminio Monforte for the Icona Foundation Study Group CD4/CD8 ratio in patients who switch therapy: better triple therapy than dual/mono? (OC 17) IX Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Siena 12-14 giugno 2017
S Rusconi, MM Santoro, A Cozzi-Lepri, A Antinori, S Bonora, A Cingolani, N Gianotti, F Ceccherini Silberstein, A Tavelli, A d'Arminio Monforte, for the Icona Foundation Study Group Factors related to over-time viral failure in HIV-infected patients with previous C-ART failures (OC 6) IX Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Siena 12-14 giugno 2017
A d'Arminio Monforte, A Antinori, A Cozzi-Lepri, F Ceccherini-Silberstein, E Girardi, A Castagna, S Lo Caputo, C Mussini, A De Luca, G Madeddu, A Cingolani, A Tavelli, G Taliani, A Gori, M Puoti and Icona Foundation Study Group. Predictors of access and response to DAA in a cohort of HIV/HCV co-infected patients in Italy. The International Liver Congress (EASL) – Amsterdam, 19/23 April 2017.

2016

1. GB Gaeta, M Shanyinde, M Puoti, A d’Arminio Monforte, A De Luca; A Castagna, A Antinori and A Cozzi-Lepri. Patients with HIV-HBV coinfection are an underestimated reservoir for Hepatitis Delta Virus. An analysis of the ICONA cohort. 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Boston – November 11-15, 2016
A Antinori, A Cozzi-Lepri , A Castagna , S Lo Caputo , C Mussini , S Rusconi , A Di Biagio, G Marchetti , S Nozza, A Cingolani, A De Luca and A d’Arminio Monforte, for the Icona Foundation Cohort Study. Prescription patterns and determinants of dolutegravir use in an antiretroviral naive HIV-infected population in Italy. 13th International Congress on Drug Therapy in HIV Infection, October 23-26, 2016 Glasgow
A Cingolani, A Cozzi Lepri, L Teofili, L Galli, V Mazzotta, G M Baldin, S Hohaus, A Bandera, L Alba, N Galizzi, A Castagna, A d'Arminio Monforte, A Antinori for ICONA Foundation Study group. Survival in HIV-1 positive individuals with diagnosis of lymphoma compared to general population. 13th International Congress on Drug Therapy in HIV Infection, October 23-26, 2016 Glasgow
A d'Arminio Monfort , P Lorenzini, A Cozzi-Lepri , C Mussini, A Castagna, F Baldelli, M Puoti, F Mazzotta, N Abrescia, S Lo Caputo, N Gianotti, A Antinori on behalf of Icona Foundation Study Group. Durability and tolerability of first-line combination with 2 NRTI and RAL or ATV/r or DRV/r in patients enrolled in the ICONA Foundation cohort. 13th International Congress on Drug Therapy in HIV Infection, October 23-26, 2016 Glasgow
G Marchetti, R Bruno, M Shanyinde , C Mussini, P Caramello, M Zaccarelli, M Andreoni, A d’Arminio Monforte and A Cozzi-Lepri for the Icona Foundation Study Group . Are HIV/HCV Co-infected patients more likely to experience multiple lines of antiretroviral therapy (ART) yhan HIV mono-infected patients? 13th International Congress on Drug Therapy in HIV Infection, October 23-26, 2016 Glasgow
M Shanyinde, G Marchetti, R Bruno, F Ceccherini-Silberstein, A Gori, A De Luca, J VecchietJ, M Lichtner, G Madeddu, P Bonfanti, A d’Arminio Monforte and A Cozzi-Lepri on behalf of the ICONA Foundation Study group. Is ART use associated with increased risk of ALT elevation in HIV/HCV co-infected patients over and above what is expected in HIV mono-infected: a nested case control study approach. 13th International Congress on Drug Therapy in HIV Infection, October 23-26, 2016 Glasgow
M Smit, R Cassidy, A Cozzi-Lepri, E Girardi, A Mammone, A Antinori, G Angarano, F Bai, S Rusconi, G Magnani, A d’Arminio Monforte, T B Hallet. Quantifying the future clinical burden of an ageing HIV-positive population in Italy: a mathematical modelling study. 13th International Congress on Drug Therapy in HIV Infection, October 23-26, 2016 Glasgow
M Zaccarelli, P Lorenzini, N Gianotti, S Rusconi, P Viale, A Chirianni, L Sighinolfi, G Parruti, A d'Arminio Monforte, A Antinori on behalf of ICONA Foundation, Study Group. Reducing Number of Pills or Number of Drugs as Strategy of HIV Treatment Simplification. Data from the Italian Icona Cohort. 13th International Congress on Drug Therapy in HIV Infection, October 23-26, 2016 Glasgow
C Mussini, A Mammone, G Marchetti, M Lichtner, A De Luca, G Lapadula, S Lo Caputo, A Antinori, A d'Arminio Monforte, E Girardi for the ICONA Foundation Study Group Risk of clinical progression among patients re-entering in care after being lost 21st International AIDS Conference (AIDS 2016); Poster TUPEB058
A d'Arminio Monforte, F. Aragão, A De Luca, F Maggiolo, A Cingolani, F Mazzotta, S Bonora, A Castagna, E Girardi, A Antinori, A Cozzi-Lepri Evolution of comorbidities in HIV patients in Italian ICONA cohort: cross sectional analysis in 2004 and 2014 21st International AIDS Conference (AIDS 2016); Poster TUPEC129
3. A Cozzi-Lepri, F Aragao, S Lo Caputo, G Guaraldi, A Ammassari, F Mazzotta, S Bonora, A Castagna, E Girardi, A Antinori and A d’Arminio Monforte on behalf of Icona Foundation Study group. Evolution of comorbidities among HIV patients in 2004 and 2014: a cross-sectional analysis from the Italian ICONA Foundation study cohort. VIII Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Milano 6-8 giugno 2016.
B Rossetti, F Bai, A Tavelli, M Galli, A Antinori, F Castelli, G Pellizzer, A Cozzi-Lepri, S Bonora, A d’Arminio Monforte, M Puoti, A De Luca, on behalf of the ICONA Foundation study group Evolution and determinants of the prevalence of HCV infection and HCV genotype distribution among HIV-infected patients entering in care between 1997 and 2015 in Italy: data from a prospective nationwide cohort (ICONA) VIII Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Milano 6-8 giugno 2016
B Coco on behalf of PITER and ICONA/HepaICONA Studies https://goo.gl/0PYVeR Clinical and virological characteristics of HIV and HCV coinfected versus HCV monoinfected patients: real life evaluation in PITER and ICONA/HepaICONA cohorts VIII Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Milano 6-8 giugno 2016
A Cozzi-Lepri, A Antinori, M Zaccarelli, F Maggiolo, G Marchetti, A Di Biagio, A Cingolani, A Castagna, A Costantini, R Piolini, A Chiodera and A d’Arminio Monforte for the Icona Foundation Study Group HIV-positive subjects treated with single tablet regimens (STR) when ART-naïve in clinical practice VIII Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Milano 6-8 giugno 2016
A Di Biagio, P Lorenzini, G Gustinetti, S Rusconi, A De Luca, G Lapadula, S Lo Caputo, S Cicalini, F Castelli, G Marchetti, A Antinori, A D’Arminio Monforte on behalf of the ICONA Foundation study group Outcomes of second line antiretroviral therapy in HIV-infected patients: data from the ICONA cohort VIII Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Milano 6-8 giugno 2016
A Cozzi Lepri on behalf of PITER and ICONA/HepaICONA Studies Access to new generation DAA treatment in HIV-negative and HIV-positive individuals with F3-F4 stage of liver disease: results from PITER and Icona/HepaICONA cohorts VIII Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Milano 6-8 giugno 2016
C Mussini, P Lorenzini, A Cozzi-Lepri, G Marchetti, S Rusconi, A Gori, N Gianotti, C Pinnetti, A Antinori, A d’Arminio Monforte CD4/CD8 ratio slope after switching from triple- to double combinations or PI-monotherapy VIII Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Milano 6-8 giugno 2016
N Gianotti, A Cozzi-Lepri, G Marchetti, A Saracino, A Gori, A Antinori, G Rizzardini, M Lichtner, A Bandera, C Mussini, E Girardi, A d'Arminio Monforte on behalf of the ICONA Foundation Study Group Drop in CD4+ counts below 200 cells/μL after reaching (or starting from) values higher than 350 cells/μL in HIV‐infected patients with virological suppression VIII Congresso Nazionale ICAR Italian Conference on AIDS and Antiviral Research - Milano 6-8 giugno 2016
F Ceccherini-Silberstein; A Cozzi-Lepri; E Merlini; G Marchetti; MR Capobianchi; A De Luca; N Gianotti; A AntinorI; CF Perno; A d'Arminio Monforte. Correlations of Pre-ART HIV-DNA With Outcome in First-Line Treated ART Patients. 23th CROI – Conference on Retrovirus and Opportunistic Infections. Boston, February 22-26, 2016.

2015

N Squillace, L Galli, A Bandera, A Castagna, G Madeddu, P Caramello , A Antinori , AM Cattelan, F Maggiolo, A Cingolani, A Gori and A d’Arminio Monforte for the ICONA Foundation study. Low High-Density Lipoprotein Cholesterol (HDL) is associated with the risk of Non-AIDS defining malignancies. 15th European AIDS Conference, Barcelona 21/24 October 2015.
M Puoti, M Shanyinde, A Antinori, A Castagna, E Nicastri, S Bonora, A Di Biagio, C Uberti-Foppa, N Abrescia, P Bonfanti, A d'Arminio Monforte, A Cozzi-Lepri, on behalf of ICONA and Hepaicona Study Group. Challenges of anti HCV treatment in persons living with HIV in the era of Directly Acting Antivirals (DAA) s. 15th European AIDS Conference, Barcelona 21/24 October 2015.
P Scognamiglio, M Shanyinde, A Gori, M Lichtner, A Di Biagio, S Lo Caputo, F Castelli, A Cozzi-Lepri, A Antinori, M Puoti, A d'Arminio Monforte, E Girardi, Icona Foundation Study. Determinants and impact of late HCV diagnosis among persons with newly diagnosed HIV infection. 15th European AIDS Conference, Barcelona 21/24 October 2015.
A Cozzi-Lepri, S Lo Caputo, F Maggiolo, A Antinori, A Ammassari, G Marchetti, C Mastroianni, A Gori, G Di Perri, G Angarano, A Carbone, A d'Arminio Monforte, on behalf of the Icona Foundation Study cohort. High treatment retention and success rates of tenofovir/emtricitabine/rilpivirine (Eviplera) in ART naïve HIV infected persons in clinical practice: a comparative study on determinants of use and treatment outcome. 15th European AIDS Conference, Barcelona 21/24 October 2015.
A Cozzi-Lepri, N Gianotti, A Antinori, A Castagna, A De Luca, BM Celesia, M Galli, C Mussini, C Pinnetti, V Spagnuolo, A d'Arminio Monforte, M Andreoni, on behalf of Icona Foundation Study and mono PI/ r database Study Cohorts. Risk and determinants of failure of a mono PI/ r simplification strategy with LPV/r or DRV/r in clinical practice. 15th European AIDS Conference, Barcelona 21/24 October 2015
G Marchetti, A Cozzi-Lepri, E Merlini, A Castagna, A Costantini, G Orofino, S Lo Caputo, A De Luca, A Antinori, A d'Arminio Monforte, Icona Foundation Study Group PrecART proinflammatory milieu, microbial translocation (MT) and risk of disease progression in HIV Infected patients starting their first cART: data from the Icona Foundation Cohort. 15th European AIDS Conference, Barcelona 21/24 October 2015.
A Antinori, A Cozzi-Lepri, A Ammassari, A Castagna, N Gianotti, S Rusconi, S Lo Caputo, F Baldelli, MS Mura, T Quirino, A Costantini, A d'Arminio Monforte, on behalf of the Icona Foundation Study Cohort. Low-level viremia (LLV) ranging from 50 to 500 copies/mL is associated to an increased risk of AIDS events in the Icona Foundation Cohort. 15th European AIDS Conference, Barcelona 21/24 October 2015.
M Lichtner, A Cozzi Lepri, S Vita, G Marchetti, A Sarracino, A Gori, C Mussini, G Madeddu, A d'Arminio Monforte, Icona Foundation Study Group. “CD4 exploders” and “CD4 peak achievers” under ART in a large Italian cohort of HIV-infected subjects. 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Vancouver, 19/22 luglio 2015.
A Mammone, R Cauda, V Vullo, C Viscoli, P Caramello, F Baldello, P Bonfanti, G Angarano, A Antinori, M Puoti, A d'Arminio Monforte, E Girardi, ICONA Foundation Study Group. Trend and causes of hospitalizations among patients with HIV entering care in Italy: a 15 years study from the ICONA cohort. 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Vancouver, 19/22 luglio 2015.
M Puoti, M Shanyinde, A Cozzi-Lepri, C Pinnetti, A Di Biagio, E Nicastri, G Viale, A De Bona, S Bonora, F Castelli, A d’Arminio Monforte on the behalf of ICONA and HepaICONA study groups. Feasibility of Pegylated Interferon (PegIFN) based therapies in HIV/HCV coinfected individuals seen for care in Italy: an estimate using data from ICONA and HepaICONA cohorts. VII Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Riccione, 17/19 maggio 2015
S Nozza, A Cozzi-Lepri, S Rusconi, A Gori, P Cinque, A Ammassari, P Caramello, G Tambussi, A d'Arminio Monforte, G Marchetti for ICONA Study Group. Prevalence of recent HIV infection (RHI) and characterisation of the RHI population in a cohort of patients seen for care in Italy over 1997-2014. VII Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Riccione, 17/19 maggio 2015
M Shanyinde, A Cozzi-Lepri, A Antinori, C Uberti Foppa, N Abrescia, P Bonfanti, G Angarano, S Bonora, A d’Arminio Monforte, MC Moioli on the behalf of ICONA and HepaICONA study groups. Characteristics of HIV/HCV co-infected individuals seen for care in Italy: a description using data from ICONA and HepaICONA cohorts. VII Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Riccione, 17/19 maggio 2015
A d’Arminio Monforte, A Cozzi Lepri, F Maggiolo, G Rizzardini, PE Manconi, N Gianotti, T Quirino, C Pinetti, S Rusconi, A De Luca, A Antinori on behalf of the Icona Foundation Study cohort. Response to first-line ritonavir-boosted protease inhibitors (PI/r) based regimens in late presenting patients enrolled in a large cohort of HIV-infected individuals. VII Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Riccione, 17/19 maggio 2015
G Marchetti, A Cozzi-Lepri, M Galli, G Rizzardini, F Maggiolo, A Antinori, T Quirino, PE Manconi, MR Capobianchi, F Ceccherini-Silberstein, A d'Arminio Monforte for the Icona Foundation Study Group. Rates of viral rebound (VR) >200 copies/mL after a viral load (VL) ≤50 copies/mL according to period and duration of viral suppression on first-line cART. VII Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Riccione, 17/19 maggio 2015
C Mussini, A d’Arminio Monforte, A Antinori, A Castagna, S Lo Caputo, F Maggiolo, M Andreoni, J Vecchiet, C Ferrari, E Nicastri, G Pellizzer, A De Luca and A Cozzi-Lepri for the Icona Foundation Study. Virological response to modern first-line antiretroviral regimens in HIV-infected patients enrolled in a large cohort according to their pre-therapy viral load and type of regimen started. VII Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Riccione, 17/19 maggio 2015
M Franzetti, A De Luca, F Ceccherini-Silberstein, V Spagnuolo, E Nicastri, C Mussini, A Antinori, L Monno, J Vecchiet, G Rizzardini, V Micheli, I Fanti, A d’Arminio Monforte, C Balotta on behalf of the ICONA Foundation Study Group. Evolution of HIV-1 Transmitted Drug Resistance in Italy in the 2009-2013 Period: a Weighted Analysis. VII Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Riccione, 17/19 maggio 2015
M Puoti, M Shanyinde, A Cozzi-Lepri, A Antinori, A Castagna, E Nicastri, S Bonora, F Castelli, A Chiodera, C Pinnetti, A d’Arminio Monforte on the behalf of ICONA and HepaICONA study groups. Direct acting anti-viral (DAA) therapeutic options in HIV/HCV co-infected individuals seen for care in Italy: an estimate using data from ICONA and HepaICONA cohorts. VII Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Riccione, 17/19 maggio 2015
A Mammone, A Cingolani, M Lichtner, A Di Biagio, P Caramello, F Baldelli, P Bonfanti, G Angarano, A Antinori, M Puoti, A d'Arminio Monforte, E Girardi, ICONA Foundation Study Group. Trend and causes of hospitalizations among patients with HIV entering care in Italy: a 15 years study from the Icona cohort. VII Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Riccione, 17/19 maggio 2015
S Vita, M Lichtner, G Marchetti, C Mascia, E Merlini, P Cicconi, V Vullo, P Luigi Viale, A Costantini, A d'Arminio Monforte. sCD163 increase in HIV/CMV coinfected subjects included in ICONA Cohort. 22nd Conference on Retroviruses and Opportunistic Infections Seattle February 23-26, 2015
A Cozzi-Lepri, A Cingolani, A Antinori, C Pinnetti A De Luca, C Mussini, S Rusconi, M Galli, A d'Arminio Monforte, A Castagna. Viremia copy years and its impact on risk of clinical progression according to shape. 22nd Conference on Retroviruses and Opportunistic Infections Seattle February 23-26, 2015
A Cingolani, P Cicconi, G Taliani, A Cozzi-Lepri, M Puoti, C Pinnetti, P L Viale, A d'Arminio Monforte. Progression of liver disease in HIV/HCV coinfected people according to gender in Icona Cohort: role of age as potential different exposure to estrogens. 22nd Conference on Retroviruses and Opportunistic Infections Seattle February 23-26, 2015

2014

G Madeddu, A d'Arminio Monforte, E Girardi, A Di Biagio, S Lo Caputo, R Piolini, G Marchetti, G Pellizzer, A Giacometti, A Galli, A Antinori, A Cozzi Lepri. on the behalf of the Icona Foundation Study Group. CD4 cell count and the risk of infective and non-infective serious non AIDS events in HIV-infected persons seen for care in Italy. 12th International Congress on Drug Therapy in HIV Infection, November 2-6, 2014 Glasgow
2. A Cingolani, S Zona, E Girardi, A Cozzi-Lepri, L Monno, E Quiros Roldan, G Guaraldi, A Antinori, A d'Arminio Monforte, S Marcotullio, on the behalf of the Icona Foundation Study Group. Increased incidence of Sexually Transmitted Diseases (STD) in the recent years: data from the ICONA cohort. 12th International Congress on Drug Therapy in HIV Infection, November 2-6, 2014 Glasgow
S Costarelli, A Cozzi-Lepri, G Lapadula, S Bonora, G Madeddu, F Maggiolo, A Antinori, A Gori, A d'Arminio-Monforte, on the behalf of the Icona Foundation Study Group. Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice. 12th International Congress on Drug Therapy in HIV Infection, November 2-6, 2014 Glasgow
N Gianotti, A Cozzi-Lepri, A Antinori, A Di Biagio, MC Moioli, S Nozza, A Cingolani, A De Luca, G Madeddu, S Bonora, F Ceccherini-Silberstein, A d’Arminio Monforte, on the behalf of the Icona Foundation Study Group. Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting. 12th International Congress on Drug Therapy in HIV Infection, November 2-6, 2014 Glasgow
A Cozzi-Lepri, S Lo Caputo, F Maggiolo, A Antinori, A Ammassari, G Marchetti, C Mastroianni, A Gori, G Di Perri, G Angarano, A Carbone, A d'Arminio Monforte, on the behalf of the Icona Foundation Study Group. Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy. 12th International Congress on Drug Therapy in HIV Infection, November 2-6, 2014 Glasgow
A Cozzi-Lepri, A Antinori, S Bonora, A Cingolani, G Cassola, G Angarano, V Vullo, C Mussini, A Gori, F Maggiolo, A Castagna, A d'Arminio Monforte, on the behalf of the Icona Foundation Study Group. An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy. 12th International Congress on Drug Therapy in HIV Infection, November 2-6, 2014 Glasgow
A Di Biagio, A Cozzi-Lepri, R Prinapori, G Angarano, A Gori, T Quirino, A De Luca, A Costantini, C Mussini, G Rizzardini, A Antinori, A d'Arminio Monforte on the behalf of the Icona Foundation Study Group. Treatment discontinuation in HIV-1 infected individuals starting their first-line HAART after 2008: data from the Icona Foundation Study Cohort. 12th International Congress on Drug Therapy in HIV Infection, November 2-6, 2014 Glasgow
A Saracino, P Lorenzini, S Lo Caputo, E Girardi, F Castelli, P Bonfanti, M Galli, P Caramello, N Abrescia, C Mussini, L Monno, A d'Arminio Monforte, on the behalf of the Icona Foundation Study Group. Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. 12th International Congress on Drug Therapy in HIV Infection, November 2-6, 2014 Glasgow
C Mussini, P Lorenzini, A De Luca, M Puoti, M Lichtner, G Lapadula, S DI Giambenedetto, A Antinori, M S Mura, A Cozzi-Lepri and A d'Arminio Monforte for the Icona Foundation. Prognostic value of FIB4 in HIV positive patients of the Icona cohort with or without HCV. 20th International AIDS Conference - July 20-25 2014, Melbourne
A Cingolani, S Zona, E Girardi, A Cozzi-Lepri, L Monno, E Quiros Roldan, G Guaraldi, A Antinori, A d'Arminio Monforte, S Marcotullio for the Community Oriented Study Group of The Icona Foundation Study Group. Increased incidence of Sexually Transmitted Diseases (STD) in the recent years: data from the ICONA cohort. VI Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Roma, 25/27 maggio 2014
A Cingolani, P Cicconi, G Taliani, G Marchetti, L Sighinolfi, F Castelli, G Cassola, D Francisci, P Caramello, L Nicolini, M Puoti, A d'Arminio Monforte for Icona Foundation Study Group and Win Study Group. Featuring HIV/HCV coinfected women in the Icona Cohort: epidemiological and clinical aspects according to gender. VI Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Roma, 25/27 maggio 2014
A Cozzi-Lepri, S Lo Caputo, F Maggiolo, A Antinori, A Ammassari, G Marchetti, C Mastroianni, A Gori, G Di Perri, G Angarano, A Carbone and A d'Arminio Monforte for the Icona Foundation. Determinants of the use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in the Icona Foundation Study. VI Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Roma, 25/27 maggio 2014
F Maggiolo, P Lorenzini, A Cozzi-Lepri, G M Corbelli, A Cingolani, E Girardi, A Antinori, A Castagna, A D'Arminio Monforte, S Marcotullio for the ICONA Foundation Study group. Outstanding outcome: in whom and how. VI Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Roma, 25/27 maggio 2014
G Madeddu, S Rusconi, A Cozzi-Lepri, S Di Giambenedetto, S Bonora, A Carbone, A De Luca, N Gianotti, A Di Biagio, A Antinori for the Icona Foundation Study Group. Efficacy and tolerability of switching to a dual therapy with darunavir/r+raltegravir in HIV-infected patientswith HIV-1 RNA ≤50 cp/mL. VI Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Roma, 25/27 maggio 2014
S Vita, M Lichtner, G Marchetti, C Mascia, E Merlini, P Cicconi,V Vullo, R Piolini, P Viale, A Costantini, C Mussini, A d'Arminio Monforte for the Icona Foundation Study. Impact of CMV infection on soluble markers of myeloid activation in HIV infected subjects. VI Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Roma, 25/27 maggio 2014
G Rozera, I Abbate, E Giombini, A Castagna, A De Luca, F Ceccherini-Silberstein, A Cozzi Lepri, G Cassola, C Torti, A d'Arminio Monforte, G Ippolito and M R Capobianchi on behalf of the ICONA Foundation Group. Analysis of peripheral HIV reservoir, tropism and soluble immune activation markers during long cART in naïve patients. VI Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Roma, 25/27 maggio 2014
C Mussini, P Lorenzini, A De Luca, M Puoti, M Lichtner, G Lapadula, S DI Giambenedetto, A Antinori, M S Mura, A Cozzi-Lepri and A d'Arminio Monforte for the Icona Foundation. Prognostic value of FIB4 in HIV positive patients of the Icona cohort with or without HCV. VI Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Roma, 25/27 maggio 2014
C Mussini, P Lorenzini, A Cozzi-Lepri, G Lapadula, G Marchetti, E Nicastri, A Cingolani, M Lichtner, A Antinori, A d’Arminio Monforte for the Icona Foundation Study Group. Incidence of CD4/CD8 Ratio Normalization and Its Role in the Onset of Non-AIDS-Related Events. 21st Conference on Retroviruses and Opportunistic Infections, March 3-6, 2014 Boston
N Squillace, P Lorenzini, G Lapadula, A Cozzi-Lepri, S Rusconi, M Puoti, A Castagna, A Antinori, A Gori, A d’Arminio Monforte for the Icona Foundation Study Group. Triglycerides/HDL Ratio and Risk of Developing Diabetes Mellitus During Antiretroviral Therapy. 21st Conference on Retroviruses and Opportunistic Infections, March 3-6, 2014 Boston

2013

A Castagna, L Monno, S Carta, L Galli, S Carrara, V Fedele, G Punzi, I Fanti, P Caramello, A Cozzi-Lepri, A De Luca, F Ceccherini-Silberstein, A d'Arminio Monforte, ICONA Foundation Study Group. The Evolution of Viral Tropism by Geno2pheno in HIV-infected Subjects with or without Virological failures after ART Initiation: Results from the ICONA Cohort. 14th European AIDS Conference, Brussels 16/19 October 2013
A Di Biagio, L A Nicolini, P Lorenzini, M Puoti, A Antinori, A Cozzi-Lepri, A Gori, J Vecchiet, C Mussini, M Andreoni, C Viscoli, A d'Arminio Monforte, ICONA Foundation Study Group. Hepatic Safety Profile of Darunavir-based Aniretroviral Treatment (ART) in HIV-1 Infected Patients with or without Hepatitis C Co-infection. 14th European AIDS Conference, Brussels 16/19 October 2013
A d'Arminio Monforte, L Galli, A Castagna, S Lo Caputo, M Lichtner, C Pinetti, N Bobbio, D Francisci, A Costantini, R Cauda, MA Forleo, E Girardi, ICONA Foundation Study Group. Aniretroviral (ART) Regimens of Pregnacy. Data from the Icona Cohort. 14th European AIDS Conference, Brussels 16/19 October 2013
A Cozzi-Lepri, MR Capobianchi, E Girardi, A De Luca, E Nicastri, P Bonfanti, P Viale, CF Perno, A d'Arminio Monforte, and A Antinori for the Icona Foundation Study. Rates of ART switching after first virological rebound >50 copies/mL according to most recent viral load pairs over 2000-2012 in clinical practice. V Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Torino, 12-14 maggio 2013
A Di Biagio, L Nicolini, P Lorenzini, M Puoti, A Antinori, ACozzi-Lepri, A Gori, J Vecchiet, C Mussini, M Andreoni, C Viscoli, A d'Arminio Monforte for the Icona Foundation Study Group. Liver-related adverse events with darunavir-based antiretroviral treatment in HIV/HCV infected patients. V Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Torino, 12-14 maggio 2013
MM Santoro, C Alteri, A Bertoli, C Gori, V Borghi, L Fabeni, I Fanti, N Orchi, C Pinnetti, C Tommasi, N Cesta, E Girardi, G D'Offizi, M Giuliani, A d'Arminio Monforte, M Andreoni, C Mussini, A Antinori, CF Perno, F Ceccherini-Silberstein. Low Prevalence of Primary Rilpivirine Mutations in NNRTI-Naïve Patients is Found in B and Most Frequent Non-B HIV-1 Subtypes in Italy. V Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Torino, 12-14 maggio 2013
S Lo Caputo, A Cozzi-Lepri, P Caramello, T Quirino, L Sighinolfi, R Cauda, S Bonora, V Vullo, A Chiodera, A Castagna, A d'Arminio Monforte for the Icona Foundation Study Group. Gender differences in ICONA cohort: epidemiological and therapeutic aspects in women with HIV infection. V Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Torino, 12-14 maggio 2013
D Armenia, MM Santoro, A Cozzi Lepri, A Calcagno, F Forbici, R Bellagamba, A Castagna, A Latini, N Petrosillo, A Ammassari, F Castelli, S Di Giambenedetto, M Andreoni, A Antinori, G Di Perri, C Mussini, F Ceccherini-Silberstein, A D'Arminio Monforte, CF Perno. Patients with very high pre-HAART viremia are at highest risk of experiencing virological rebound. V Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Torino, 12-14 maggio 2013
A Cingolani, A Cozzi-Lepri, C Mussini, A Ammassari, A De Luca, P Caramello, G Castelli, E Girardi, A Antinori, A d'Arminio Monforte, for the ICONA Foundation Study. Patterns of cART regimens use and virological response according to specific AIDS-defining events (ADE) in AIDS-presenter patients over time. V Congresso Nazionale ICAR Italian Conference on AIDS and Retroviruses - Torino, 12-14 maggio 2013
M Puoti, P Lorenzini, E Girardi, A Cozzi-Lepri, A Gori, C Mastroianni, G Rizzardini, G Mazzarello, A Antinori, A d'Arminio Monforte, and Icona Foundation Study Group1 Incidence and Progression to Cirrhosis of HCV Superinfection in Persons Living with HIV (PLHIV) 20th Conference on Retroviruses and Opportunistic Infections 3-6 March 2013 Atlanta

2012

A Cozzi-Lepri, A Antinori, E Magistrelli, F Castelli, G Rizzardini, A Castagna, G Pellizzer, N Abrescia, G Parruti, T Quirino, P Castelli, J Vecchiet, G d'Annunzio, A d'Arminio Monforte. Durability of FTC/TDF-containing cART regimens in a large cohort of HIV-infected patients seen for care in Italy. Eleventh International Congress on Drug Therapy in HIV. 11 International Congress on Drug Therapy in HIV Infection, November 11-15, 2012 Glasgow (Oral 313)
M Lichtner, P Cicconi, S Vita, A Cozzi-Lepri, M Galli, S Lo Caputo, G Angarano, A De Luca, F Moioli, F Maggiolo, G Marchetti, V Vullo, A d'Arminio Monforte. CMV co-infection and risk of AIDS and non- AIDS events in a large cohort of HIV-infected patients. 11 International Congress on Drug Therapy in HIV Infection, November 11-15, 2012 Glasgow (Oral 415)
A Cingolani, A Cozzi-Lepri, A Ammassari, C Mussini, G Magnani, P Caramello, G Angarano, P Bonfanti, A De Luca, MS Mura, E Girardi, A Antinori, A d'Arminio Monforte. Timing of cART initiation after a first AIDS-defining event (ADE): temporal changes in clinical attitudes in a large cohort of HIV-infected patients. 11 International Congress on Drug Therapy in HIV Infection, November 11-15, 2012 Glasgow (Oral 422)
A d'Arminio Monforte, A Cozzi-Lepri, G di Perri, M Andreoni, M Galli, A Poli, F Maggiolo, A Costantini, G Viscoli, L Sighinolfi, G Rizzardini, P Bonfanti, N Gianotti, CF Perno, A Antinori. Durability of lopinavir/r monotherapy in people with viral load ≤ 50 copies/ml. 11 International Congress on Drug Therapy in HIV Infection, November 11-15, 2012 Glasgow (P305)
A Ammassari, P Lorenzini, C Mussini, A Cozzi-Lepri, F Baldelli, A Gori, M Andreoni, V Tozzi, G Di Perri, A Lazzarin, T Quirino, G Cassola, A d'Arminio Monforte, A Antinori. Impact of antiretroviral dosing frequency and daily pill burden on virological success rates in patients of the ICoNA cohort starting their first ART. 11 International Congress on Drug Therapy in HIV Infection, November 11-15, 2012 Glasgow (P 262)
C Alteri, VC Di Maio, A Artese, G Costa, MM Santoro, S Alcaro, M Andreoni, A Antinori A, F Ceccherini-Silberstein, CF Perno, V Svicher. Structural modifications in HIV-1 RT induced by specific RT polymorphisms tighly modulate the first phase of viraemia decay to first line FTC+TDF containing HAART. International on HIV & Hepatitis virus Drug Resistance Workshop & curative strategies, June 5-9 2012, Melia Sitges, Sitges
G Rozera, I Abbate, E Giombini , A Castagna, A De Luca, F Ceccherini Silberstein, A Cozzi Lepri, G Cassola, G Carosi, G Ippolito, MR Capobianchi. Dynamics of X4 variants in HIV-1 quasispecies over a five years of interval in patients under cart. 10th European Meeting on HIV& Hepatitis Treatment Strategies & Antiviral Drug Resistance, March 28-30 2012, Barcelona, Spain, Reviews in Antiviral Therapy & Infectious Diseases 2/2012 #O_20 p 21 Oral Presentation
C Alteri, VC Di Maio, A Artese, G Costa, S Alcaro, M Andreoni, A Antinori, F Ceccherini-Silberstein, CF Perno, V Svicher. Specific RT Polymorphisms Tightly Modulate Virological Response to First Line FTC+TDF containing HAART and Affect the RT Interaction with FTC and/or TDF. 19 th Conference on Retroviruses and Opportunistic Infections 5-8 March 2012 Seattle
G Lapadula, A Cozzi-Lepri, A Gori, A Antinori, G Marchetti, A Chiodera, P Narciso, G Parruti, M Galli, A d'Arminio Monforte. Risk of AIDS and non AIDS-related events among patients with conserved CD4+ T-cell counts at baseline but blunted immune-response despite virological suppression after antiretroviral treatment. 19 th Conference on Retroviruses and Opportunistic Infections 5-8 March 2012 Seattle
F Sabbatini, A Cozzi-Lepri, A Bandera, G Madeddu, S Bonora, V Tozzi, C Mastroianni, P Bonfanti, A Gori, A d'Arminio Monforte. Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of Italian HIV-Infected People. 19th Conference on Retroviruses and Opportunistic Infections, March 5-8, 2012 Seattle (P868)

2011

C Mussini, A Cozzi-Lepri, A Antinori, A Castagna, S Lo Caputo, G Pellizzer, F Maggiolo, M Andreoni, J Vecchiet, C Ferrari, L Galli, A d'Arminio Monforte, Icona Foundation. Viro-immunological response to the first cART regimen according to baseline viral load: an observational study. 13th European AIDS Conference/EACS, October 12-15, 2011 Belgrade (PE7.9/4)
A Cozzi-Lepri, C Mussini, S Bonora, MR Capobianchi, A De Luca, V Tozzi, G Parruti, A Giacometti, C Viscoli, A Orani, V Vullo, A d'Arminio Monforte, Icona Foundation Study. The chance of suppressing viral load ≤80 copies/mL according to initial viral load and type of regimen started: an observational study. 13th European AIDS Conference/EACS, October 12-15, 2011 Belgrade (PE7.7/3)
A Cozzi-Lepri, A De Luca, A Castagna, A Antinori, G Cassola, G Rizzardini, T Quirino, N Abrescia, C Torti, G Pagano, A d'Arminio Monfote, Icona Foundation Study. Response to emtricitabine- vs. lamivudine-containing combination antiretroviral therapy (cART) with tenofovir in patients enrolled in a large cohort in Italy. 13th European AIDS Conference/EACS, October 12-15, 2011 Belgrade (PE7.4/1)
S Lo Caputo, A Cozzi-Lepri, A Antinori, M Galli, PL Viale, A Lazzarin, G Carosi, L Sighinolfi, M Montroni, A d'Arminio Monforte for the ICONA Foundation Study Group. HIV treatment guidelines and value of CD4 count at ART initiation. Data analysis of a cohort of HIV patients enrolled in Italy when their CD4 count was >500 cells/mm3. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 17-20, 2011 Rome. Abstract TUPBD01
A d'Arminio Monforte, A Cozzi-Lepri, M Puoti, M Arlotti, P Narciso, A Gori, P Caramello, A Chiodera, G Cassola, CM Mastroianni for the Icona Foundation Study group. Durability of emtricitabine vs. lamivudine in patients enrolled in a large cohort in Italy starting tenofovir containing combination antiretroviral therapy (cART). 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 17-20, 2011 Rome. Abstract CDB275
R Murri, A Ammassari, MP Trotta, A Antinori, P Lorenzini, A d'Arminio Monforte. Health-care delivery characteristics of clinical centers are correlated with survival of Italian HIV patients. ICAR 2011, 39(SI):S24
MM Santoro, V Svicher, A Cozzi-Lepri, L Fabeni, B Bruzzone, C Mussini, A De Luca, M Andreoni, I Fanti, A Antinori, M Zazzi, CF Perno, A d'Arminio Monforte, F Ceccherini-Silberstein for Icona Foundation. Impact of natural polymorphisms of HIV-1 reverse transcriptase at position 135 on virologic response to a first line NNRTI-containing HAART. 15th International Workshop on HIV Observational Databases. Prague, Czech Republic, March, 24-26, 2011. Abstract 83
MM Santoro, C Alteri, I Abbate, V Svicher, A Bruselles, B Bartolini, C Gori, G Rozera, MR Capobianchi, CF Perno, F Ceccherini-Silberstein. Sentinel Mutations in Standard Population Sequencing Predict a high prevalence of RTI-resistance minor variants in both RNA plasma and DNA cellular samples from HIV-1 drug naïve patients. SIVIM. 4th National Congress of Italian society of medicine virology oral presentation Milano, 5-7 May, 2011
C Alteri, MM Santoro, L Fabeni, C Gori, V Cento, F Stazi, G Maffongelli, M Viscione, M Zaccarelli, P Narciso, M Andreoni, A Antinori, F Ceccherini-Silberstein, V Svicher, CF Perno. The presence of PR compensatory mutations increases over the years and correlates with a shorter time to virological failure in PI treated patients. 9th European Workshop on HIV & Hepatitis. Cyprus, March 23 -25, 2011. Abstract O_06
G Marchetti, A Cozzi-Lepri, GM Bellistri, E Merlini, F Ceccherini-Silberstein, A De Luca, A Antinori, A Castagna, M Puoti, A d'Arminio Monforte for the Icona Foundation Study Group. Role of Immune Activationand Microbial Translocation in Liver Disease progression in HIV/HCV Co-infected ARV-naïve patients with high CD4+ Count. 18th Conference on Retroviruses and Opportunistic Infections, Boston, February 27-March 2 2011. (abs 936)
A Cingolani, A Cozzi-Lepri, A Castagna, D Goletti, A De Luca, P Scarpellini, I Fanti, A Antinori, A d'Arminio Monforte, E Girardi and Icona Foundation, ICC, UCSC, HSR Cohort Study. Impaired CD4 Count response to cART ina ARV-naïve HIV-infected PatientsPresenting with TB as an AIDS-defining Condition. 18th Conference on Retroviruses and Opportunistic Infections, Boston, February 27-March 2 2011. (abs 885)
MP Trotta, P Lorenzini, M Bibas, M Galli, G Rizzardini, P Narciso, V Tozzi, L Pucillo, A d'Arminio Monforte, A Antinori and Icona Foundation Study. Relative prognostic value of Serum-Free Light Chains and Effective HAART in Predicting HIV-associated Lymphoma and Mortality. 18th Conference on Retroviruses and Opportunistic Infections, Boston, February 27-March 2 2011. (abs 863)

2010

G Marchetti, A Cozzi-Lepri, G Bellistrì, E Merlini, F leoncini, F baldelli, G Antonucci, A Castagna, E Raise, L Manzini, PE Manconi, M Puoti, A De Luca, A d'Arminio Monforte for the Icona Foundation Study Group. Role of microbial translocation (MT) and immune Hyperactivation (IH) in liver disease progression of HIV/HCV+ patients with well documented HIV seroconversion date and preserved CD4 count. Infection 2010, 38(SI):85
A Cozzi-Lepri, M Prosperi, S Lo Caputo, C Gervasoni, C Mussini, M Andreoni, A Gori, G Cristini, A d'Arminio Monforte for the Icona Foundation Study. Fib4 is an independent predictor of serious liver disease among HIV-infected patients with or without HBV/HCV co-infection in the Icona Foundation Study. Infection 2010, 38(SI):73
V Svicher, V Cento, C Gori, M Ciccozzi, M Arlotti, M Puoti, N Ladisa, G Rizzardini, A d'Arminio Monforte, CF Perno, and Icona Foundation Study Group. The synergistic interaction between immunological and pharmacological selective pressure in HIV-HBV co-infected patients is a potent driver of HBV evolution and drug resistance emergence. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010. (abs. 637)
M Borderi, F Vescini, A Cozzi-Lepri, A Di Caro, I Shlacht, G Cassola, G Pellizzer, J Vecchiet, MC Re, A d'Arminio Monforte, for the Icona Foundation Study Group. Prevalence of hypovitaminosis D among HIV+ patients enrolled in a large Italian Cohort. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010. (abs. 751)
G Marchetti, A Cozzi-Lepri, G M Bellistrì, E Merlini, A Chiodera, F Soscia, G Rizzardini, MR Capobianchi, A De Luca, A d'Arminio Monforte, for the Icona Foundation Study Group. Role of microbial translocation and immune hyperactivation in disease progression of HIV+ patients with preserved CD4 count in the absence of ART. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010. (abs. 333)

2009

E Girardi, C Angeletti, P Scognamiglio, MCF Prosperi, A d'Arminio Monforte, A Castagna, A De Luca, C Torti, G Scalise, G Rizzardini, L Caggese, A Antinori, G Ippolito, Icona Foundation. Determinants of access to investigational antiretrovirals among Italian HIV infected patients. 12th European AIDS Conference/EACS, November 11-14, 2009 Cologne (PE10.4/6)
A De Luca, K de Gaetano Donati, A Cozzi-Lepri, M Colafigli, A De Curtis, MR Capobianchi, A Antinori, G Scalise, G Magnani, V Vullo, R Cauda, L Iacoviello, A d'Arminio Monforte, ICoNA Foundation Study Group. Exposure to abacavir and biomarkers associated with cardiovascular disease (CVD) in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study. 12th European AIDS Conference/EACS, November 11-14, 2009 Cologne (PE9.5/8)
A d'Arminio Monforte, A Cozzi-Lepri, I Fanti, F Maggiolo, A Castagna, F Prati, V Vullo, T Quirino, P Narciso, S Lo Caputo, E Girardi, C Mussini, A Antinori, Icona Foundation Study Group. Proportion and trend over calendar time of patients with a low CD4 count or AIDS diagnosis at the time of their first contact with clinical care in Italy. 12th European AIDS Conference/EACS, November 11-14, 2009 Cologne (LS 2/2)
A De Luca, M Colafigli, K de Gaetano Donati, A Cozzi-Lepri, A De Curtis, A Gori, F Ghinelli, G Scalise, F Carletti, A D'Avino, L Iacoviello, R Cauda, A d'Arminio Monforte, ICoNA Foundation Study Group. Inflammatory biomarkers predict cardiovascular events in HIV positive patients receiving cART: a case control study. 12th European AIDS Conference/EACS, November 11-14, 2009 Cologne (PS 11/5)
M Zaccarelli, A Antinori, A Cozzi-Lepri, C Mussini, G Palamara, MM Santoro, V Spagnuolo, A d'Arminio Monforte, CF Perno, F Ceccherini-Silberstein. Is there any potential for first line Etravirine use? Analysis from a large dataset of ART-naïve HIV infected patients undergoing resistance test. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 19-22, 2009 CapeTown
A De Luca, K De Gaetano Donati, A Cozzi-Lepri, A De Curtis, MR Capobianchi, A Antinori, G Scalise, G Magnani, V Vullo, R Cauda, L Iacoviello, A d'Arminio Monforte, ICONA Foundation Study Group. Abacavir treatment and biomarkers associated with cardiovascular disease (CVD) in HIV-1 infected patientson effective antiretroviral therapy. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 19-22, 2009 CapeTown
A d'Arminio Monforte, A Cozzi-Lepri, A Antinori, A De Luca, C Mussini, S Lo Caputo, G Cassola, G Pellizzer, J Vecchiet, P Caramello, M Montroni, A Castagna, Icona Foundation Study Group. Framingham risk score in HIV-positive patients living in Italy: the Icona Foundation Study. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 19-22, 2009 CapeTown
A Ammassari, A Cozzi-Lepri, A De Luca, E Girardi, M Arlotti, C Torti, M Ladisa, P Piano, E Raise, C Mussini, A Castagna. A relatively slow risk of diseases progression in HIV-positive patients with indolent infection has been found in the Icona Cohort. Infection 2009, 37(SII):106
MCF Prosperi, A Cozzi-Lepri, A Castagna, C Mussini, R Murri, A Costantini, G Antonucci, A Gori, G Mazzarello, A Antinori, A d'Arminio Monforte for the Icona Foundation Study. The risk and determinants of Malignancies in HIV-infected patients enrolled in the Icona Foundation Study. Infection 2009, 37(SII):30
A Cozzi-Lepri, A Antinori, A De Luca, P Bonfanti, G Cassola, M Andreoni, G Pellizzer, J Vecchiet, G Carnevale, GC Orofino, A d'Arminio Monforte for the Icona Foundation Study Group. An exploratory analysis to ssess the potential effect of art in modifying the Framingham risk score in HIV-infected patients enrolled in the Icona Foundatipn Study. Infection 2009, 37(SII):25
C Alteri, V Svicher, V Cento, C Gori, R Salpini, F Marcucilli, A Bertoli, M Arlotti, M Puoti, N Ladisa, G Rizzardini, M Andreoni, F Ceccherini-Silberstein, A d'Arminio Monforte, CF Perno and the Icona Study Group. Characteristic of Lamivudine resistance profiles in HBV riverse transcriptase from a national collaborative study of HIV+HBV infected individuals on long-exposure to lamivudine including regimens. Infection 2009, 37(SII):32
V Svicher, D Armenia, MM Santoro, F Forbici, B Bruzzone, M Setti, P Corsi, R Maserati, C Mussini, M Zazzi, A De Luca, A Andreoni, P Narciso, A Antinori, CF Perno, F Ceccherini-Silberstein. Impact of mutations at position 135 of HIV-1 reverse transcriptase on virologic response to a first line NNRTI-containing HAART. Infection 2009, 37(SII):33
V Svicher, C Alteri, V Cento, C Gori, R Salpini, F Marcucilli, A Bertoli, M Arlotti, M Puoti, N Ladisa, G Rizzardini, F Ceccherini-Silberstein, A d'Arminio Monforte, CF Perno and the Icona Study Group. Novel patterns of Mutations in HBV Riverse Transcriptase Associated with Lamivudine Resistance in HBV+HIV Co-infected Patients. Antiviral Therapy, 2009 14:S1A68
V Svicher, C Gori, R Salpini, M Trignetti, S Romano, R Longo, M Bernassola, F Marcuccilli, G Rizzardini, GM De Sanctis, F Ceccherini-Silberstein, G Cappiello, A Spanò, A d'Arminio Monforte, C Perno. HIV-driven Immuno-suppression modulates HBV Evolution in HBV/HIV-co-infected Patients. 7th European HIV Drug Resistance Workshop, Stockholm, Sweden, March 25-27 2009
V Svicher, M Trignetti, C Gori, S Romano, A Bonomini, G Rizzardini, F Ceccherini-Silberstein, A Spanò, A d'Arminio Monforte, C Perno, and ICONA Study Group. HIV-driven Immunosuppression Regulates HBV Evolution in HBV/HIV-co-infected Patients. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, February 8-11 2009. (abs. 99)

2008

M Bongiovanni, A Cozzi-Lepri, A Castagna, A Antinori, A De Luca, C Mussini, S Lo Caputo, C Arici, M Puoti, A d'Arminio Monforte, and ICONA Foundation Study Group. HIV+ Subjects Co-infected with HBV or HCV Have a Higher Risk of Developing AIDSdefining Malignancies. 15th Conference on Retroviruses and Opportunistic Infection, February 3-6 2008, Boston

2007

A Castagna, L Galli, C Torti, A d'Arminio Monforte, C Mussini, A Antinori, A Cozzi-Lepri, N Ladisa, A De Luca, A Lazzarin, IDD-HSR Cohort, Master Cohort, Icona Cohort, Modena Cohort. Predicting Magnitude of Short-term CD4 Recovery in HIV Infected Patients during First-line HAART. 11th European AIDS Conference/EACS, Madrid, October 24-27, 2007. (abs. P7.9/07)
A De Luca, A Cozzi-Lepri, A Antinori, C Mussini, C Torti, M Puoti, C Gervasoni, N Abrescia, M Arlotti, A Orani, V Vullo, A Chirianni, A d'Arminio Monforte, ICONA Foundation Study Group. Initiating cART after an AIDS-defining Condition: Treatment Outcomes and their Determinants in ICONA. 11th European AIDS Conference/EACS, Madrid, October 24-27, 2007. (abs. P18.4/08)
F Ceccherini-Silberstein, V Svicher, MM Santoro, MCF Prosperi, F Forbici, A Bertoli, A De Luca, C Mussini, G Palamara, P Narciso, A Antinori, C Balotta, A d'Arminio Monforte, CF Perno, ICoNA Study Group, INMI-Collaborative Group for Clinical Use of HIV Ge Impact of HIV-1 Reverse Transcriptase Polymorphism R83K on Virological Response in Drug-Naïve Patients starting Thymidine Analogue Containing HAART. 11th European AIDS Conference/EACS, Madrid, October 24-27, 2007. (abs. P3.4/19)
P Cicconi, A Cozzi-Lepri, A De Luca, A Antinori, A Castagna, C Mussini, A d'Arminio Monforte, and I.Co.N.A. Cohort. CDB249. Insights into the reasons for discontinuation and changes in the durability of the first line cART over time in Icona (Italian cohort of naïve antiretrovirals). 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sidney, July 22-25, 2007 (abs. CDB249)
F Tordato, P Cicconi, A Cozzi-Lepri, A De Luca, A Antinori, C Mussini, T Quirino, C Arici, A Gori, A d'Arminio Monforte, and I.CO.N.A cohort. Evaluation of glomerular filtration rate (GFR) in naïve HIV positive patients. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sidney, July 22-25, 2007 (abs. CDB166)
M Bongiovanni, A Gori, A Cozzi-Lepri, A Antinori, A De Luca, G Pagano, A Chiodera, M Puoti, A d'Arminio Monforte. Is CD4 percentage a better marker of immune-suppression than CD4 absolute count in HIV-infected subjects with cirrhosis? 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sidney, July 22-25, 2007 (abs. MOPEB063)
A Ammassari, MP Trotta, P Marconi, R Murri, A d'Arminio Monforte, A Antinori for the AdICoNA Study Group. Length of clinic visit affects adherence to antiretroviral therapy. 8th International Conference AIDS Impact. Marseille, France. 1st - 4th July 2007
MP Trotta, A Ammassari, P Marconi, R Murri, A d'Arminio Monforte, A Antinori. Sexual dysfunction in HAART-treated persons: prevalence, determinants and relationship with adherence. 8th International Conference AIDS Impact. Marseille, France. 1st - 4th July 2007.
I Malet, L Fabeni, S Dimonte, S Bono, V Svicher, R D'Arrigo, P Flandre, A Antinori, A d'Arminio Monforte, C Katlama, V Calvez, CF Perno, AG Marcelin, F Ceccherini-Silberstein. Specific mutations associated with in-vitro resistance to HIV-1 integrase inhibitors are present in untreated and NRTI/NNRTI/PI-treated HIV-infected patients. 5th European HIV Drug Resistance Workshop, From Basic Science to Clinical Implications. Cascais, Portugal, March 29-31, 2007. Abstract book: 46 pag 34.
V Svicher, T Sing, A Artese, MM Santoro, C Gori, S Alcaro, A Bertoli, A d'Arminio Monforte, A Antinori, T Lengauer, F Ceccherini-Silberstein, CF Perno. Involvement of Two Additional HIV-1 Reverse Transcriptase Mutations in the Regulation of NNRTI Resistance. 5th European HIV Drug Resistance Workshop, From Basic Science to Clinical Implications. Cascais, Portugal, March 29-31, 2007. Abstract book: 117 pag 92.
A Antinori, A Cozzi-Lepri, P Cinque, M Giancola, A De Luca, C Mussini, C Torti, L Sighinolfi, V Colangeli, A d'Arminio Monforte, and ICoNA Cohort. Could Cerebrospinal Fluid ART Penetration Scores Predict Viral Rebound in ART-naïve Individuals Who Achieve Plasma Viral Load Suppression on Their First Therapy? 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 25-28 2007. (abs. 382a).
A Ammassari, A Cozzi-Lepri, M Trotta, P Marconi, C Torti, A Castagna, A De Luca, V Colangeli, A Antinori, A d'Arminio Monforte, and ICoNA Cohort. Treatment Complexity and Risk of Virological Rebound in Persons Receiving cART. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, February 25-28 2007. (abs. 522)

2006

F Ceccherini-Silberstein, V Svicher, T Sing, MM Santoro, A Bertoli, F Forbici, A Artese, A d’Arminio Monforte, A Antinori, and CF Perno. Additional mutations in HIV-1 reverse transcriptase involved in regulation of NNRTI resistance. 4rd European HIV Drug Resistance Workshop, From Basic Science to Clinical Implications. Monte Carlo, Monaco, March 29 – 31, 2006. (abs. 95)
A Cossarizza, A Riva, B Zanone Poma, P Cicconi, M Nasi, V Broggini, M Pinti, A Cozzi-Lepri, A d’Arminio Monforte, M Galli, and LipoICONA Study Group. FASI-670 and APOC3 polymorphisms as predictors of lipoatrophy in patients receiving antiretroviral therapy. 13th Conference on Retroviruses and Opportunistic Infections, Denver, February 5-8 2006. (abs. 767)
P Cicconi, A Cozzi-Lepri, M Puoti, G Antonucci, M Mannazzu, G Pastore, M Mena, A Phillips, A d’Arminio Monforte and I.Co.N.A. Study Group. Is the increased risk of liver enzyme elevation in hepatitis co-infected patients greater in those on HAART than in antiretroviral-naive patients? 13th Conference on Retroviruses and Opportunistic Infections, Denver, February 5-8 2006. (abs. 888)

2005

MP Trotta, A Cozzi-Lepri, A Ammassari, P Marconi, D Repetto, G Madeddu, N Ladisa, P Nasta, A Riva, M Lichtner, CM Izzo, M Dalessandro, A d’Arminio Monforte, A Antinori, AdIcona Study Group. Patterns of non-adherence predict virological response differently according to antiretroviral drug classes. X European AIDS Conference/EACS, 17-20 November 2005 Dublin, Ireland (abs. PE10.1/4)
A Cozzi-Lepri, A De Luca, AN Phillips, M Bongiovanni, S Di Giambenedetto, M Mena, C Moioli, M Arlotti, L Sighinolfi, P Narciso, M Lichtner, R Cauda, A d’Arminio Monforte. A comparison between abacavir and efavirez when used as the “third group” with a background therapy of two NRTIs in patients with initially suppressed viral load. X European AIDS Conference/EACS, 17-20 November 2005 Dublin, Ireland (abs. PE7.4/8)
R Murri, A Cozzi-Lepri, G Vigevani, R Piscopo, D Bertelli, MA Ursitti, A Riva, S Nappa, E Manzillo, A d’Arminio Monforte. Reasons for delaying the starting of antiretroviral therapy (ART) shor an association with clinical outcomes. X European AIDS Conference/EACS, 17-20 November 2005 Dublin, Ireland (abs. PS1/2)
M Galli, A Cozzi-Lepri, AL Ridolfo, A Cappelletti, P Morelli, E Giannelli, A Radice, S Trovati, F Mazzotta, M Montroni, A Cargbel, A d’Arminio Monforte, C Gervasoni, M Moroni, for LipoIcona Study Group. Triglyceride level predicts lipoatrhphy in patients receiving antiretroviral therapy. X European AIDS Conference/EACS, 17-20 November 2005 Dublin, Ireland (abs. PS5/1)
P Cicconi, L Sighinolfi, A Cozzi-Lepri, C Basilico, G Di Perri, A Chiodera, R Viglietti, M D’Alessandro, A d’Arminio Monforte, and I.Co.N.A. Study Group. Clinical Prognosis of HIV-positive patients older than 50 years in the I.Co.N.A. cohort. 3rd IAS Conference on HIV Pathogenesis and Treatment. Rio de Janeiro, July 2005. (abs. MoPe11.6C07)
P Cicconi, M Puoti, A Cozzi Lepri, L Cosco, G Morsica, T Santantonio, F Ancarani, A Cargnel, A d’Arminio Monforte, and I.Co.N.A. Study Group. Risk factors for decompensated cirrhosis and associates morbidity and mortality in I.Co.N.A. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, July 2005. (abs. TuPe1.1C24)
P Cicconi, A Cozzi Lepri, M Puoti, S Pasquinucci, P Pizzaferri, E Petrelli, F Leoncini, A Alessandrini, A d’Arminio Monforte, and I.Co.N.A. Study Group. Incidence of grade 3 hepato-toxicity (HT) according to different antiretrovirals in a cohort oh HIV-1-positive and HbsAg/HCVAb-negative patients in I.Co.N.A. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, July 2005. (abs. TuPe2.3C16)
V Svicher, F Ceccherini-Silberstein, T Sing, M Santoro, N Beerenwinkel, F Rodriguez, F Forbici, A d’Arminio Monforte, A Antinori, and CF Perno. Additional mutations in HIV-1 reverse transcriptase are involved in the highly ordered regulation of NRTI resistance. 3th European HIV Drug Resistance Workshop, From Basic Science to Clinical Implications, 30 March-1 April 2005, (abs. 63)
MP Trotta, S Bonora, A Cozzi-Lepri, A Ammassari, P Marconi, N Ladisa, P Nasta, L Sighinolfi, M Zaccarelli, A Riva, G Madeddu, P De Longis, A d’Arminio Monforte, G Di Perri, A Antinori and AdICoNA Study Group. Durability of viral suppression according to self-reported non-adherence and antiretroviral plasma levels. 12th Conference on Retroviruses and Opportunistic Infections, 22-25 February, 2005, Boston, USA (abs. 644)

2004

A De Luca, A Cozzi-Lepri, A Antinori, M Zaccarelli, A d’Arminio Monforte, M Bongiovanni, S Di Giambenedetto, D Zinzi, P Cicconi, F Resta, B Grisorio, S D’Elia, R Cauda for the ICoNA Study Group. Lopinavir/r or efavirenz plus two NRTI as first-line antiretroviral therapy: a non randomised comparison. VII International Congress on Drug Therapy in HIV infection, 14-18 November 2004 Glasgow, UK (abs. P26)
A Ammassari, MP Trotta, P Marconi, R Murri, A Cozzi-Lepri, S Melzi, M Zaccarelli, P De Longis, G Bontempo, N Ladisa, L Sighinolfi, P Nasta, G Madeddu, A d’Arminio Monforte, A Antinori. Incorporating patients’ suggestions in individualized intervention program for improving adherence to antiretrovirals. VII International Congress on Drug Therapy in HIV infection, 14-18 November 2004 Glasgow, UK (abs. P97)
MP Trotta, A Ammassari, A Cozzi-Lepri, P Marconi, R Murri, P De Longis, N Ladisa, M Zaccarelli, G Bontempo, P Nasta, G Madeddu, A d’Arminio Monforte, A Antinori. Changes in adherence to highly active antiretroviral therapy medications and determinants of worsening adherence: results from the AdICoNA Study. VII International Congress on Drug Therapy in HIV infection, 14-18 November 2004 Glasgow, UK (abs. P117)
F Ceccherini-Silberstein, M Santoro, S Svicher, C Gori, F Gago, T Hermsen, M Ciccozzi, M Ruiz Alvarez, R D'Arrigo, A Bertoli, S Giannella, A Cenci, MP Trotta, C Balotta, A d'Arminio Monforte, A Antinori and CF Perno. High conservation of the HIV-1 reverse transcriptase under drug pressure is maintained despite a continuous appearamce of mutations. HIV Medicine 2004; 5 (abstract 39)
G Antonucci, A Cozzi-Lepri, E Petrelli, G Carnevale, PA Grossi, P Viganò, A d'Arminio Monforte, MR Capobianchi, M Solmone, E Girardi, F Carletti, G Ippolito for the ICoNA Study Group. The role of GBV-C viraemia and HCV viraemia in the response to antiretroviral therapy in a cohort of HIV-infected subjects. XV International AIDS Conference, 11-16 July 2004, Bangkok - Thailand (abs. WeOrB1328)
M Galli, A Cozzi-Lepri, AL Ridolfo, V Vullo, M Montroni, A Cappelletti, P Morelli, A d'Arminio Monforte, C Gervasoni, M Moroni. Correlates of risk of concomitant presentation of lipoatrophy, lipohypertrophy and hypertriglyceridemia in HIV-positive patients on first-line antiretroviral therapy. XV International AIDS Conference, 11-16 July 2004, Bangkok - Thailand (abs. WePeB5936)
A d'Arminio Monforte, P Cicconi, A Cozzi-Lepri, A Matteelli, G Orlando, A Alessandrini, M Mena, MC Moioli, P Ortolani, D Bertelli, M Montroni, M Moroni for the ICoNA Study Group. Sexually transmitted diseases (STD) in the I.Co.N.A (Italian CohortNaive Antiretrovirals) study: prevalence and incidence on 5422 patients. XV International AIDS Conference, 11-16 July 2004, Bangkok - Thailand (abs. WeOrB1330)
F Ceccherini-Silberstein, M Santoro, S Svicher, C Gori, F Gago, M Ciccozzi, M Ruiz Alvarez, R D’Arrigo, A Bertoli, S Giannella, A Cenci, MP Trotta, A d’Arminio Monforte, A Antinori an CF Perno. High conservation of the HIV-1 reverse transcriptase under drug pressure. 11th Conference on Retroviruses and Opportunistic Infections, 8-11 February 2004, San Francisco, USA (abs. 643)

2003

E Girardi, MS Aloisi, C Arici, P Pezzotti, D Serraino, R Balzano, GM Vigevani, F Alberici, M Ursitti, M D’Alessandro, A d’Arminio Monforte, G Ippolito for the I.CO.N.A. Behavioural Epidemiology Study Group. Delayed presentation and late testing for HIV: demographic and behavioural risk factors in a multicenter study in Italy. 9th European AIDS Conference (EACS), 25-29 October 2003, Warsaw, Poland (abs. F5/2)
A De Luca, A Cozzi-Lepri, CF Perno, C Balotta, S Di Giambenedetto, A Orani, C Mussini, M Toti, A d’Arminio Monforte for the I.CO.N.A. Study Group. The prognostic value to predict virological outcomes of 14 distinct systems used to interpret the results of genotypic HIV-1 drug resistance testing in untreated patients starting their first HAART. 9th European AIDS Conference (EACS), 25-29 October 2003, Warsaw, Poland (abs. F6/7)
M Galli, A Cozzi-Lepri, AL Ridolfo, A Cappelletti, P Morelli, E Gianelli, M Piazza, F Mazzotta, M Montroni, U Tirelli, A Cargnel, A d’Arminio Monforte, C Gervasoni, M Moroni for the LipoICONA Study Group. Are the early manifestations of Lypodistrophy predicted by serum triglyceride level in patients receiving antiretroviral therapy? 9th European AIDS Conference (EACS), 25-29 October 2003, Warsaw, Poland (abs. F16/1)
C Riva, M Violin, A Cozzi-Lepri, R Velleca, F Forbici, R Novati, F Castelli, M Bonasso, V Colangeli, G Rezza, G Ippolito, CF Perno, A d’Arminio Monforte, M Moroni, C Balotta for the I.CO.N.A. Study Group. Transmitted resistance mutations in a cohort of recent seroconvertes in Italy: temporal pattern and prevalence accordino to HIV-1 subtype. 9th European AIDS Conference (EACS), 25-29 October 2003, Warsaw, Poland (abs. 3.1/3)
A d’Arminio Monforte, A Cozzi-Lepri, C Balotta, R Velleca, C Gori, A Antinori, G Angarano, F Mazzotta, GP Cadeo, R Maserati, CF Perno for the I.CO.N.A Study Group. The degree of viral suppression predicts the probabilità of accumulatine new drug-mutations at virological failure to the first PI-HAART regimen. 9th European AIDS Conference (EACS), 25-29 October 2003, Warsaw, Poland (abs. 3.4/11)
6. MP Trotta, A Ammassari, A Cozzi-Lepri, P Marconi, S Melzi, M Zaccarelli, R Murri, P De Longis, G Bontempo, N Ladisa, L Sighinolfi, F Castelli, G Madeddu, N Abrescia, M Lichtner, J Vecchiet, G Orofino, A d’Arminio Monforte, A Antinori for the AdICoNA2 Study Group. Relationship between four adherence measurements and CD4 count response. 9th European AIDS Conference (EACS), 25-29 October 2003, Warsaw, Poland (abs. 10.1/19)
A Ammassari, MP Trotta, A Cozzi-Lepri, A De Luca, S Melzi, M Zaccarelli, F Castelli, P Narciso, F Soscia, R Murri, A Scasso, CM Izzo, F Baldelli, A d’Arminio Monforte, A Antinori for the AdICoNA2 Study Group. HAART non-adherence and HCV/HIV co-infection. 9th European AIDS Conference (EACS), 25-29 October 2003, Warsaw, Poland (abs. 13.2/20)
A d'Arminio Monforte, A Cozzi-Lepri, R Murri, R Novati, A Antinori, C Arici, V Colangeli, A De Luca, N Ladisa, E Girardi, M Moroni for the I.Co.N.A. Study Group The effect of HAART interruptions on clinical progression: evidence from I.CO.N.A.. cohort. Antiviral Therapy 2003; 8(suppl 1): S219
A Cozzi-Lepri, S Kinloch, C Arici, AN Phillips, D Santoro, P Narciso, F Lompe and A d'Arminio Monforte for the I.CO.N.A. Study Group The pre-therapy CD4 count and the duration of safe HAART interruption (HI) in patients (pts) who discontinue all their drugs with a CD4 count > 200 cells/mmc. Antiviral Therapy 2003; 8(suppl 1): S350
MP Trotta, A Ammassari, A Cozzi-Lepri, S Melzi, P Marconi, N Abrescia, P De Longis, V Vullo, M Zaccarelli, A Scalzini, V Tozzi, R Murri, E Boumis, A d'Arminio Monforte and A Antinori Sexual dysfunction (SD) in HAART-treated persons: prevalence, determinants and relationship with adherence (ADH). Antiviral Therapy 2003; 8(suppl 1): S399
MS Aloisi, C Arici, P Noto, R Piscopo, G Filice, F Menichetti, A d'Arminio Monforte, G Ippolito, E Girardi and Behepi Study Group. Behavioural correlates of adherence to antiretroviral therapy. AIDS impact 2003, 6th International Conference on Biopsychosocial Aspects of HIV infection, 7-10 July 2003, Milan, Italy
MS Aloisi, L Gennero, S Di Cesare, S Nappa, A La Gala, A Antinori, G Ippolito, A d'Arminio Monforte, F Starace and Neuroicona Study Group. One-year incidence of minor cognitive impairment in a cohort of HIV patients: findings from the Neuroicona Study. AIDS impact 2003, 6th International Conference on Biopsychosocial Aspects of HIV infection, 7-10 July 2003, Milan, Italy
CF Perno, A Cozzi-Lepri, C Balotta, F Forbici, A De Luca, S Rusconi, MS Mura, MC Moioli, A Scalzini, M Lichtner, AN Phillips, A d’Arminio Monforte for the I.CO.N.A. Study Group. Mutation M36I in the HIV protease before starting therapy is predictive of L90M primary mutation at the time of first PI-HAART failure. 1st European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications, March 6-8, 2003, Luxembourg. (abs. 1:P1.1)
M Violin, R Velleca, C Riva, S Corvasce, M Montroni, N Petrosillo, G Antonucci, A Poggio, F Forbici, CF Perno, A d’Arminio Monforte, M Moroni and C Balotta. Analysis of HIV-1 mutants with unreported variants at position 215 of RT region. 1st European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications, March 6-8, 2003, Luxembourg. (abs. 2:P1.2)
C Riva, M Violin, A Cozzi-Lepri, R Velleca, PA Grossi, E Raise, D Santoro, A Sinicco, G Rezza, CF Perno, A d’Arminio Monforte, M Moroni and C Balotta. HIV-1 non-B subtypes and circulating recombinant forms increased in Italy in recently infected individuals over the 1996-2002 period. 1st European HIV Drug Resistance Workshop: from Basic Science to Clinical Implications, March 6-8, 2003, Luxembourg. (abs. 58:P4.7)
CF Perno, A Cozzi-Lepri, C Balotta, F Forbici, M Violin, A De Luca, S Rusconi, G Ballardini, E Petrelli, E Tufo, AN Phillips, A d’Arminio Monforte. Mutation 36I of the protease region bifore starting therapy facilitates the appearance of L90M in patients failing their first PI-HAART regimen. 10th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003, Boston, USA. (abs. 602)
F Ceccherini-Silberstein, A Bertoli, F Forbici, F Erba, L Marcon, S Aquaro, C Balotta, S Giannella, R D’Arrigo, MC Bellocchi, C Gori, MP Trotta, A d’Arminio Monforte, A Antinori, CF Perno. Identification of the minimal conserved structure of the HIV-protease under the presence and absence of drug pressare. 10th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003, Boston, USA. (abs. 595)
G Nasti, R Talamini, A Antinori, F Martellotta, M Fasan, F Chiodo, G Ballardini, L Stoppini, G Di Perri, M Mena, M Tavio, E Vaccher, A d’Arminio Monforte, U Tirelli. AIDS-related Kaposi’s Sarcoma in 211 patients: assessment of the AIDS clinical trial group staging classification prognostic value in the era of HAART. 10th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003, Boston, USA. (abs. 815)

2002

R Murri, A Cozzi Lepri, AP Phillips, E Girardi, G Nasti, S Ferrara, MS Mura, C Mussini, E Petrelli, M Arlotti, C De Stefano, P Viganò, L Gennero, B Salassa, G Antonucci, P Narciso, S Chigiotti, T prestileo, R Novati, A Cargnel, A d’Arminio Monforte. Access to antiretroviral treatment, incidence of sustained therapy interruptions and risk of clinical events according to gender:evidence from the I.CO.N.A. study. 6th International Congress on Drug Therapy in HIV Infection, 17-21 November 2002, Glasgow (abs. PL6.4)
A Ammassari, A Cozzi Lepri, MP Trotta, A Cappelletti, S Melzi, P De Longis, M Zaccarelli, V Vullo, R Murri, P Piano, S Lo Caputo, S Nappa, F Baldelli, A d’Arminio Monforte, A Antinori, M Galli for the AdICONA and the LipoICONA Study Group. Adherence (ADH) to HAART is predictive of developing of adipose tissue alterations (ATA) and is negatively affected by patient-reported fat accumulation. 6th International Congress on Drug Therapy in HIV Infection, 17-21 November 2002, Glasgow (abs. P85)
MP Trotta, A Ammassari, R Murri, A Cozzi Lepri, C Minardi, G Orofino, L Tacconi, F Alberici, P Noto, G Nasti, M Ciardi, A d’Arminio Monforte, A Antinori. Patient-report, physician-estimate and drug plasma levels as measures for adherence to HAART in the AdICONA study. 6th International Congress on Drug Therapy in HIV Infection, 17-21 November 2002, Glasgow (abs. P89)
A Antinori, A Cozzi Lepri, MP Trotta, GC Fibbia, P Narciso, E Manzillo, J Vecchiet, A Vincenti, M De Marco, C Mussini, A d’Arminio Monforte, A Ammassari for the AdICONA Study Group. Predictive value of self-reported non-adherence (non-adh) and drug plasma levels on viral rebound in HAART-treated patients with undetectable viremia. 6th International Congress on Drug Therapy in HIV Infection, 17-21 November 2002, Glasgow (abs. P177)
M Galli, AL Ridolfo, A Cozzi Lepri, A d’Arminio Monforte, C Gervasoni, M Vaccarezza, A Cappelletti, A Chirianni, F Mazzotta, U Tirelli, A Scalzini, P Morelli, E Gianelli, M Piazza, M Moroni. Risk factors for the development of hypercholesterolaemia, hypertriglyceridaemia and abnormal glucose levels in the LipoICONA cohort. 6th International Congress on Drug Therapy in HIV Infection, 17-21 November 2002, Glasgow (abs. P131)
M Galli, A Cozzi-Lepri, C Gervasoni, AL Ridolfo, F Mazzotta, C De Stefano, N Piersantelli, E Pizzigallo, E Gianelli, M Piazza, M Vaccarezza, A Cappelletti, A d’Arminio Monforte, M Moroni for the LipoICONA Study Group. Triglyceridaemia, but not cholesterolaemia and glycaemia, is a predictor of lipodystrophy: the results of LipoICONA longitudinal study. 4TH International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego (USA) 22-25 September 2002 (abs. 41)
M Violin, A Cozzi-Lepri, R Piscopo, A Giacometti, CF Perno, A d’Arminio Monforte, C Balotta for the I.CO.N.A. Study Group. The pattern of primary resistance to antiretrovirals in Italy after HAART therapy. XIV International AIDS Conference, Barcellona (Spain) July 7-12, 2002 (abs. ThPeB7217)
E Girardi, C Arici, M S Aloisi, D Serraino, F Delfanti, M C Moioli, M Ciardi, M De Marco, E Manzillo, G Ippolito on behalf of ICONA-BehEpi Study. Determinants of delayed presentation to medical care after testing HIV positive. XIV International AIDS Conference, Barcellona (Spain) July 7-12, 2002 (abs. WePeC6158)
MS Aloisi, E Girardi, D Serraino, M Ferrara, P Ortolani, G Tositti, L Tacconi, GC Fibbia, L Sighinolfi, G Ippolito on behalf of ICONA-Behavioural Epidemiology (BEHEPI) Study. Sexual risk behaviours after initiating HAART therapy among people living with HIV. XIV International AIDS Conference, Barcellona (Spain) July 7-12, 2002 (abs. ThPeD7765)
G Antonucci, A Cozzi-Lepri, M Solmone, A De Luca, C Pastecchia, G Madeddu, P Piano, A Vincenti, F Carletti. No difference in virological and immunological response to HAART according to HCV genotype and viral load in a cohort of HIV/HCV co-infected patients. XIV International AIDS Conference, Barcellona (Spain) July 7-12, 2002 (abs. WePeB6029)
A Antinori, M P Trotta, A Cozzi Lepri, M Zaccarelli, L Minardi, P Narciso, L Ravasio, R Murri, F Baldelli, P Piano, S Lo Caputo, P De Longis, P Noto, S Nappa, M Dalessandro, AW Wu, M Moroni, G Ippolito, A d'Arminio Monforte, A Ammassari. Adherence to antiretroviral therapy: comparative analysis of protease inhibitors-based and non-nucleoside reverse transcriptase inhibitors-based regimens. XIV International AIDS Conference, Barcellona (Spain) July 7-12, 2002 (abs. WePeB5852)
A Antinori, A Cozzi-Lepri, A Ammassari, MP Trotta, R Hoetelmans, L Ravasio, M Zaccarelli, L Minardi, R Murri, V Tozzi, P Santopadre, A Scasso, F Soscia, C Izzo, M Ciardi, J Vecchiet, P Caramello, N Abrescia, AW Wu, G Ippolito, M Moroni, A d'Arminio Monforte. Self-reported non-adherence but not drug plasma levels is predictive of viral rebound in HAART-treated patients with undetectable viraemia. Results of the AdICoNA Study Group. XIV International AIDS Conference, Barcellona (Spain) July 7-12, 2002 (abs. MoPpB2011)
C Riva, M Violin, A Cozzi-Lepri, R Velleca, A Bertoli, P Viganò, L Minoli, A Orani, G Rizzardini, T Zauli, CF Perno, A d'Arminio Monforte and C Balotta for the I.Co.N.A. Study Group Transmitted virus with substitutions at position 215 and risk of virological failure in antiretroviral-naive patients starting highly active antiretroviral therapy. XIV International AIDS Conference, Barcellona (Spain) July 7-12, 2002 (abs. 124)

2001

A De Luca, A Cozzi-Lepri, C Arici, R Piscopo, G Cadeo, A Orani, ML Soranzo, A d’Arminio Monforte for the ICONA Study Group. The effect of age, drug class, HCV coinfection and viral inhibition on the long term immunologic recovery of antiretroviral-naïve subjects undergoing HAART. 8th European Conference on clinical aspects and treatment of HIV infection, Athens (Greece) 28-31 October 2001 (abs. P22)
S Corvasce, R Mazzucchelli, A Cozzi-Lepri, F Ghinelli, G Pagano, G Ippolito, A d’Arminio Monforte, M Moroni G Rezza and C Balotta for the ICONA Study Group. Role of CCR5-delta32, CCR2-641 and SDF 1-3’A alleles in a population of HIV-1 patients with known date of seroconversion. 8th European Conference on clinical aspects and treatment of HIV infection, Athens (Greece) 28-31 October 2001 (abs. P30)
A Cozzi-Lepri, AN Phillips, A d’Arminio Monforte, E Raise, E Rinaldi, V Colangeli, P Narciso, L Bonazzi and M Moroni or the ICONA Study Group. Virological and immunological response to nevirapine or efavirenz in combination with two nucleoside analogues in the ICONA Study. 8th European Conference on clinical aspects and treatment of HIV infection, Athens (Greece) 28-31 October 2001 (abs. P45)
R Bugarini, A d’Arminio Monforte, G Nasti, P Viganò, S Mancuso, C Moioli, N Petrosillo, G Antonucci, E Petrelli for the ICONA Study Group. Determinants of the choice of the first HAART regimen. 8th European Conference on clinical aspects and treatment of HIV infection, Athens (Greece) 28-31 October 2001 (abs. P51)
A Ammassari, A Antinori, P Pezzotti, MS Aloisi, MP Trotta, R Murri, P De Longis, L Ravasio, G D’Offizi, M Zaccarelli, CM Izzo, S Nappa, A d’Arminio Monforte, G Ippolito, AW Wu, F Starace and the AdICONA and NeuroICONA Study Groups. Relationship of depression, neurocognitive impairment and HAART adherence. 8th European Conference on clinical aspects and treatment of HIV infection, Athens (Greece) 28-31 October 2001 (abs. P79)
R. Murri, A. Ammassari, P Pezzotti, MP Trotta, R Hoetelmans, L Ravasio, P De Longis, S Lo Caputo, P Narciso, S Pauluzzi, G Carosi, S Nappa, PE Manconi, CM Izzo, P Santopadre, A Scasso, F Soscia, S D’Elia, P Caramello, J Vecchiet, A Scalzini, G Rezza, G Ippolito, A d’Arminio Monforte, AW Wu, A Antinori for the AdICoNA Study Group. Patient-physician concordance on adherence to HAART: prevalence and determinants. 8th European Conference on clinical aspects and treatment of HIV infection, Athens (Greece) 28-31 October 2001 (abs. LB/P7)
MS Aloisi, R Murri, E Girardi, M Ferrara, D Serraino, A d’Arminio Monforte, M Moroni, G Ippoliti and ICONA-BEHEPI Study Group. Assessment of mental health (MH)among antiretroviral naive women living with HIV in Italy: The ICONA-BEHEPI Study. 8th European Conference on clinical aspects and treatment of HIV infection, Athens (Greece) 28-31 October 2001 (abs. P355)
M Galli, AL Ridolfo, C Gervasoni, L Ravasio, L Corsico, E Giannelli, M Vacarezza, A Cargnel, A d’Arminio Monforte, M Moroni for the LipoICONA Study Group. Socio-behavioural factors and HCV coinfection influence the risk of presenting fat tissue alterations in first line antiretroviral therapy. 8th European Conference on clinical aspects and treatment of HIV infection, Athens (Greece) 28-31 October 2001 (abs. P108)
A Ammassari, R Murri, P Pezzotti, MP Trotta, R Hoetelmans, L Ravasio, P De Longis, S Lo Caputo, P Narciso, S Pauluzzi, G Carosi, S Nappa, P Piano, CM Izzo, M Lichtner, G Rezza, G Ippolito, A d’Arminio Monforte, Aw Wu, A Antinori for the AdICONA Study Group. Symptoms and medication side effects as determinant of self-reported non-adherence to HAART are related to antiretroviral plasma levels. 8th European Conference on clinical aspects and treatment of HIV infection, Athens (Greece) 28-31 October 2001 (abs. P152)
A d’Arminio Monforte, A Cozzi Lepri, C Balotta, F Forbici, M Violin, A Bertoli, G Facchi, V Colangeli, A Vincenti, A De Luca, F Soscia, G Ippolito, CF Perno. 3TC-related mutations and response to therapy. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, February 4-8, 2001 (abs. 447)

2000

M Galli, A Cozzi-Lepri, AL Ridolfo, C Gervasoni, L Ravasio, L Corsico, E Gianelli, V Vullo, A Cargnel, L Minoli, F Gritti, G Scalise, A Antinori, G Antonucci, A d'Arminio Monforte, M Moroni for the LipoICONA Study Risk of developing adipose tissue alterations after starting antiretroviral therapy in naive patients. 2nd International Workshop on Adverse Drug Reactions and lipodystrophy in HIV. Toronto, Canada, 13-15 September 2000, (abs. P60)
A d’Arminio Monforte, R Bugarini, Pezzotti, A Sinicco, F Menichetti, S Pauluzzi, A Chirianni, P Grima, F Resta for the I.CO.N.A Study Group. Changes in triglycerides and cholesterol in response to HAART in Italian Cohort Naive Antiretrovirals (I.CO.N.A). XIII International AIDS Conference, Durban 9-13 July 2000 (abs. WePeB4242)
P Pezzotti, R Bugarini, A Aceti, F Alberici, G Filice, A Scalzini, F Ghinelli, A Alessandrini, F Leoncini for the I.CO.N.A Study Group. Incidence and factors associated with the occurrence of severe hepatic cytolysis in the ICONA study. XIII International AIDS Conference, Durban 9-13 July 2000 (abs. TUPpB1161)
A d’Arminio Monforte, A Cozzi-Lepri, C Balotta, G Facchi, F Forbici, A Colomba, M Arlotti, A Antinori, CF Perno. Prevalence of antiretroviral drugs-related mutations in a large cohort of HIV-1 positive antiretroviral-naive patients and its correlation with viral load and CD4 count at the time of genotypic testing. XIII International AIDS Conference, Durban 9-13 July 2000 (abs. TuPeB3273)
C Balotta, M Violin, S Van Dooren, A Berlusconi, G Facchi, F Forbici, A Bertoli, G Rezza, CF Perno, A d’Arminio Monforte, AM Vandamme, M Moroni for the I.CO.N.A. Study Group. Increasing prevalence of non-clade B HIV-1 strains in Italy, as monitored by the analysis of the RT and protease sequences. 4th International Workshop on HIV Drug Resistance & Treatment Strategies. Sitges, 12-16 June 2000 (abs. 181)
C Balotta, M Violin, G Facchi, A Berlusconi, E Manzillo, C Minardi, S Garavaglia, L Cremonini, G Tositti, A Cozzi-Lepri, G Rezza, CF Perno, A d’Arminio Monforte for the I.CO.N.A. Study Group. Risk of HAART failure is related to the presence of trasmitted mutations conferring resistance to RT inhibitors in HIV-1 newly infected individuals. 4th International Workshop on HIV Drug Resistance & Treatment Strategies. Sitges, 12-16 June 2000 (abs. 187)
C Balotta, A Cozzi-Lepri, M Violin, G Facchi, M Salemi, A Berlusconi, F Gritti, M Montroni, B Grisorio, CF Perno, A Lazzarin, G Angarano, G Rezza and A d’Arminio Monforte for the I.CO.N.A. Study Group. HIV-1 primary transmitted mutations and HIV-1 subtyping in a cohort of induviduals recently infected with HIV-1. Second Frankfurt Symposium on the clinical implications of HIV drug resistance. Frankfurt, 25-27 February 2000 (abs. 8)
CF Perno, C Balotta, A Cozzi-Lepri, F Forbici, M Violin, A Bertoli, PE Manconi, A Poggio, P Caramello, F Soscia, L Monno, G Ippolito, A d’Arminio Monforte for the I.CO.N.A. Study Group. Selected secondary mutations in the protease region can be independent predictors of virological failure in antiretroviral naive patients treated with protease inhibitors containing HAART regimens. Second Frankfurt Symposium on the clinical implications of HIV drug resistance. Frankfurt, 25-27 February 2000 (abs. 4)
A d’Arminio-Monforte, CF Perno, C Balotta, A Cozzi-Lepri, F Forbici, A Bertoli, M Violin, P Pezzotti, F Mazzotta, E Raise, L Monno, G Angarano, F Dianzani, G Ippolito and M Moroni for the I.Co.N.A. Study Group. Prevalence of pol gene Mutations In A Cohort of Antiretroviral-Naïve Patients: Correlation with HIV RNA and CD4 Count at the Time of Genotypic Testing. VII Conference on Retroviruses and Opportunistic Infections. San Francisco, January 30-February 2, 2000 (abs. 747)
CF Perno, A d’Arminio-Monforte, A Cozzi-Lepri, C Balotta, F Forbici, A Bertoli, P Pezzotti, G Facchi, L Monno, G Angarano, P Bottura, V Vullo, A Cargnel, MR Capobianchi, G Ippolito, and M Moroni for the I.CO.N.A. Study Group. Mutations at Codons 10 and 36 of Protease Region in Absence of Primary Mutations May Correlate with Virological Outcome in Naive Patients Starting a PI-Containing HAART Regimen. VII Conference on Retroviruses and Opportunistic Infections. San Francisco, January 30-February 2, 2000 (abs. 728)

1999

A d’Arminio Monforte, A Cozzi Lepri, P Pezzotti, G Rezza, AN Phillips, N Abrescia, L Bonazzi, GP Cadeo, A Cargnel, F De Lalla, C De Stefano, M Piazza, S Ranieri, ML Soranzo, V Vullo for the I.CO.N.A. Study Group. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen and its determinants. Seventh European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon 23-27 October, 1999 (abs. 121)
P Pezzotti, R Bugarini, A d'Arminio Monforte, G Rezza, A Aceti, A Chirianni, B De Rienzo, W Grillone, P Grima, F Mazzotta, M Montroni, S Pauluzzi, E Raise, A Scalzini, P Viganò for the I.CO.N.A. Study Group. Factors associated to immunologic and virologic response in the first 24 months of combination therapy in a large observational cohort study. Seventh European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon 23-27 October, 1999 (abs. 221)
G Rezza, A Cozzi-Lepri, P Pezzotti, A d'Arminio Monforte, P Cadrobbi, G Carnevale, S D'Elia, T Ferraro, GP Fiori, R Piscopo, E Pizzigallo, G Scalise, A Scasso, F Suter, M Toti, for the I.CO.N.A. Study Group. Lower levels of HIV-RNAin women compared to men in a population of antiretroviral naïve patients (I.CO.N.A. Study) with known duration of HIV infection. Seventh European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon 23-27 October, 1999 (abs. 410)

1998

A d’Arminio Monforte, C Arici, G Ippolito, G Rezza, F Dianzani, M Moroni, for the I.CO.N.A. Group. Issues of Italian Cohort Naive Antiretroviral (ICONA) study and enrollment data. 12th World AIDS Conference. Geneva, June 28-July 3 1998; (abs. 60929).
MS Aloisi, E Girardi, M Carballo, A d’Arminio Monforte, C Arici, G Ippolito. Patient perspective of clinical disease and care in cohort of people with HIV/AIDS antiretrovirals therapies naives. 12th World AIDS Conference. Geneva, June 28-July 3 1998; (abs. 12452)
MS Aloisi, E Girardi, M Carballo, A d’Arminio Monforte, C Arici, G Ippolito. Perception of the risk of transmitting HIV among people living with HIV/AIDS presently cared for in the italian health system. 12th World AIDS Conference. Geneva, June 28-July 3 1998; (abs.23521)
MS Aloisi, E Girardi, M Carballo, A d’Arminio Monforte, G Ippolito for the ICONA Behepi-study. Assessment of behavioural patterns a cohort of naive antiretrovirals HIV-infected persosns. 2eme Conférence européenne sur les methodes et les résultats des Recherches en sciences sociales sur le SIDA. Parigi, 12-15 Janvier 1998; (abs. Wo 15.1)

Publications

La raccolta di tutte le pubblicazioni di Fondazione ICONA,...

Congressi